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AntibioticInadequate dosing and incomplete treatment regimens, coupled with the ability of the tuberculosis bacilli to
cause latent infections that are tolerant of currently used drugs, have fueled the rise ofmultidrug-resistant tuber-
culosis (MDR-TB). Treatment of MDR-TB infections is a major clinical challenge that has few viable or effective
solutions; therefore patients face a poor prognosis and years of treatment. This review focuses on emerging
drug classes that have the potential for treatingMDR-TB and highlights their particular strengths as leads includ-
ing their mode of action, in vivo efﬁcacy, and key medicinal chemistry properties. Examples include the newly
approved drugs bedaquiline and delaminid, and other agents in clinical and late preclinical development pipeline
for the treatment ofMDR-TB. Herein,we discuss the challenges to developing drugs to treat tuberculosis and how
the ﬁeld has adapted to these difﬁculties, with an emphasis on drug discovery approaches that might produce
more effective agents and treatment regimens.
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Mycobacterium tuberculosis (Mtb) has been a major human patho-
gen since the dawn of modern human existence, with the evolution of
modern Mtb sublineages closely correlating with the different waves
of human migration out of Africa [1]. As the human race began to
form denser population centers, culminating in urbanization, Mtb
spread more easily, and it became one of the leading causes of death
by the beginning of the twentieth century. The prognosis for patients
with tuberculosis (TB) improved dramatically with the discovery and
introduction of antitubercular drugs, starting with streptomycin in
1946 and subsequent research that produced today's frontline therapies
for drug-sensitive Mtb. It is important to note that despite having an
effective treatment regimen, Mtb still caused an estimated 9 million
infections and 1.5 million deaths in 2013 [2].
The current standard of care for drug-susceptible Mtb infection is
very effective in bacillary clearance, provided full compliance by the
patient. A 2-month “intensive” phase of a four-drug cocktail containing
rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol
(EMB) (Fig. 1) is followed by a longer “continuation” phase of RIF and
INH to eradicate the remaining bacilli that have entered a dormant,
slowly replicating latent phase. A looming global issue hidden in the
midst of this epidemic was the emergence of drug-resistant bacteria, a
trend that is on the rise, as such strains are easily spreadwith lowﬁtness
costs associatedwith transmission [3,4]. TheWorld Health Organization
(WHO) reported that globally 3.5% of naive infections already expressed
resistance to the two most efﬁcacious frontline agents used to treat the
disease, RIF and INH, thereby classifying the infection as multidrug-
resistant tuberculosis (MDR-TB) [2]. Treatment of drug-susceptible
Mtb is difﬁcult already, requiring 6–9 months of combination therapy
in ideal circumstances. Complicating the issue is that Mtb tends to be
endemic to the developing world; thus, access to adequate healthcare
facilities and drugs can be limited for those patients. This leads to in-
complete treatments, a leading driver for conferring drug resistance;
20.5% of patients with relapsed disease have MDR-TB [2].
Treatment for MDR-TB can extend upwards of 2 years and relies on
more toxic, less efﬁcacious second- or third-line agents, many of whichFig. 1. Current frontline agents used to treat drug-susceptible Mtb.are even more scarce than frontline drugs in affected areas [5]. A very
common and deadly complication of Mtb infection is coinfection with
human immunodeﬁciency virus (HIV) [6,7]. This is particularly trouble-
some because RIF, a mainstay in Mtb therapy, is a potent inducer of
drug-metabolizing enzymes, including cytochrome P450 (CYP) 3A4.
This induction dramatically reduces plasma levels of several highly ac-
tive antiretroviral therapy drugs; thus, patients are often forced to com-
plete their TB treatment before beginning HIV treatment [6–9]. Patients
who contract MDR-TB with HIV have a very poor prognosis due to the
duration of treatment; these individuals frequently succumb within a
few months.
The urgent need to develop new active agents to combat MDR-TB
has been compounded by the emergence of extensively drug-resistant
tuberculosis (XDR-TB) [10], deﬁned as MDR-TB with additional resis-
tance to ﬂuoroquinolones and one of the injectable second-line agents.
Furthermore, cases of totally drug-resistant tuberculosis (TDR-TB) have
been noted in China, India, Africa, and Eastern Europe. In TDR-TB, the
mycobacterium are resistant to all available therapeutics [11]. Combin-
ing the decline in efﬁcacy of known active agentswith the dearth of new
chemical entities being moved into the clinic setting, we have reached
the point where a “postantibiotic” era is a very real possibility [12].
From a clinical perspective, the WHO's approach to reduce the number
of TB deaths and infections is to implement directly observed treatment,
short course. This regimen implements the following ﬁve main
elements to increase survival and decrease transmittance for most
developing countries: (1) government commitment to monitoring and
treating Mtb infections, (2) sputum-smear microscopy for all cases to
assess drug susceptibility, (3) standardized treatment regimenswith di-
rect observation by a trained healthcare professional, (4) uninterrupted
drug supply, and (5) standardized reporting system to maximize data
interpretation directly from patients' medical records. This approach
has reduced the overall number of TB infections and deaths, but it has
not affected the increasing numbers of MDR-TB infections [13].
Therefore, more chemotherapeutic interventions are needed.
New agents would ideally have the following attributes: a novel
mechanism of action to attenuate cross-resistance; rapid bactericidal
activity to reduce duration of therapy; optimized pharmacokinetic/
pharmacodynamic (PK/PD) properties for once-daily oral administra-
tion; low potential for drug–drug interactions to allow combination
therapy, especially with other TB drugs and current HIV therapeutics;
and excellent safety proﬁle to allow for use in children and pregnant
women. These ideal criteria are coupled with other practical goals
such as inexpensive manufacturing, high compound stability, narrow
spectrum of activity, high tolerability, and a low rate of spontaneous-
resistance emergence.
In recent years, we have seen the ﬁrst regulatory approvals for new
Mtb drugs (i.e., bedaquiline and delamanid) in decades (Fig. 2) [14,15].
Both drugs have been conditionally approved [delamanid in the
European Union's EuropeanMedicines Agency (EMA) [16]] because ad-
verse events have been noted. TheU.S. Food andDrug Agency (FDA) has
approved bedaquiline for MDR-TB and delamanid as a compassionate
care option for XDR-TB and TDR-TB infections, and the EMA approved
both agents for MDR-TB. The fact is that these drugs have pronounced
issues, including hERG toxicity concerns, as well as multiple ADME is-
sues due to their high lipophilicity. A lack of viable alternatives in late-
stage clinical development is indicative of the state of drug discovery
in this ﬁeld, and innovation to drive new projects is desperately needed.
In this review, we discuss up-and-coming drug classes with demon-
strated in vivo efﬁcacy that are on the cusp of entering clinical trials.
Fig. 2. Two recently approved antitubercular agents developed speciﬁcally for MDR-TB
infections.
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they may possess in targeting MDR-TB in replicating and more latent
forms, and their prospects moving into the clinic.
1.1. Resistance in Mtb
Drug resistance in Mtb was noted soon after the introduction of
streptomycin, the ﬁrst drug to treat tuberculosis. Exposure to a drug in-
duces stress responses inside the infected cell that favors both genetic
and physiological mechanisms that lead to colony survival. Current an-
titubercular drugs are commonly associated with speciﬁc resistance
mutations (Table 1).Table 1
Clinically relevant antitubercular drugs and their commonly associated resistance mechanisms
Drug name Mechanism of action Com
res
Rifampicin RNA synthesis inhibition Mu
cau
Isoniazid Mycolic acid biosynthesis inhibitor and effects
on DNA, lipid, carbohydrate, and NAD
metabolism
Kat
reg
Pyrazinamide Not fully resolved, may include membrane
potential disruption
Mu
Ethambutol Arabinogalactan biosynthesis inhibition Mu
Amikacin/Kanamycin Protein synthesis inhibition 16S
Inc
Capreomycin Protein synthesis inhibition Cro
me
Streptomycin Protein synthesis inhibition Mu
Fluoroquinolones DNA gyrase and topoisomerase IV inhibitor Mu
gen
efﬂ
Ethionamide Mycolic acid biosynthesis inhibition Mu
ove
Cycloserine Peptidoglycan biosynthesis inhibition Ove
Para-aminosalicyclic acid Folic acid and iron metabolism inhibition Mu
mu
Clofazimine Release of Reactive Oxygen Species (ROS) and
cell membrane disruption
Mu
(cro
Linezolid Protein synthesis inhibitor (50S subunit) T46
me
ß-lactam/ß-lactamase inhibitor:
Amoxicillin
Meropenem
Imipenem
Cell wall disruption via peptidoglycan
modulation
Ove
dea
me
Thiacetazone Inhibits methyltransferases in mycolic acid
biosynthesis
eth
deh
Clarithromycin Protein synthesis inhibition (50S subunit) Low
mo
Bedaquiline Inhibition of mitochondrial ATP synthase atp
(cro
Delamanid Mycolic acid biosynthesis inhibition MuMostMtb resistance observed in the clinic can be attributed to inde-
pendent, spontaneousmutations that interferewith the drug binding to
the target protein, reduce prodrug-activating enzymes, or overexpress
an essential target [17]. For a more detailed analysis of the molecular
basis of resistance to currently used agents, we refer readers to a review
by Palomino et al. [18]. In recent years, our ability to study resistance
mechanisms has been greatly aided by the availability of whole-
genome sequencing. This cutting-edge technology has not only shed
light on many direct and indirect routes of resistance but also added in-
sight into the function of some altered genes, thereby providing crucial
information about newdrug targets and rationale for future drug design
studies. For example, extensive knowledge has been gained in the areas
of lipidmetabolism, cell wall homeostasis, purinemetabolism, and tran-
scriptional regulation [19]. However, many resistant strains that have
been sequenced express additional or unique mutations that differ
from commonly associated alterations. Resistance mutations often
have an associatedﬁtness cost [20], i.e., the physiological penalty for de-
veloping said drug resistance is that the Mtb's growth may be limited
in vivo. Bacteria can overcome this ﬁtness via compensatory mutations
that allow the organism to act more energetically (similar to the wild-
type bacteria), while maintaining resistance. An example from MDR-
TB clinical isolates in Russia identiﬁed rpoA and rpoC as compensatory
mutations in RIF-resistant strains [21]. These genes are mutated to alle-
viate the ﬁtness costs associated with the drug-resistant rpoBmutation
thatmodulates the binding site at theβ-subunit of the RNA polymerase.
Medicinal chemistry strategies to target drug-resistant TB infections in-
clude designing agents that have novel mechanisms of action and are
thus not prone to cross-resistance or redesign of inhibitors to target
themutant enzyme form, and identiﬁcation and development of agents
for which the ﬁtness cost of further resistance development is high..
mon mechanism of
istance
tation of rpoB induces a conformational change at β-subunit of RNA polymerase
sing a decrease in binding afﬁnity
G suppression causing decreased prodrug activation, and a mutation in the promoter
ion of InhA causing an overexpression of InhA
tations in pncA reducing conversion to active acid form
tations in embB at codon embB306
rRNA target site modulation (1400 and 1401 rrs gene)
reased drug inactivation via overexpression of eis aminoglycoside acetyltransferase
ss-resistance with aminoglycosides plus mutation of tlyA which decreases rRNA
thyltransferase activity
tations in rpsL and rrs confer binding site modulation
tations in gyrA and gyrB causing an alteration to DNA Gyrase A/B binding site (later
erations not always cross-resistant with ﬁrst generation) and increased ABC-type
ux pump expression
tations in ethA and inhA causing decreased prodrug activation and InhA
rexpression (cross-resistance with Isoniazid)
rexpression of alrA decreasing drug efﬁciency
tations in the thyA causing a decrease in activated drug concentrations and folC
tations which cause binding site mutations
tation to Rv0678 causes upregulation of MmpL5, a multisubstrate efﬂux pump
ss-resistance with Bedaquiline)
0C mutation in rplC, encoding the 50S ribosomal L3 protein and possible efﬂux
chanisms
rexpression of β-lactamases, (BlaC), point mutations at target site altering
cylation rate and binding afﬁnity, cell permeability (alteration in porins and outer
mbrane composition), and increased efﬂux (Rv0194)
Amutation minimizes prodrug activation and mutations to hadABC operon affecting
ydratase activity
cell wall permeability and the expression of emr37, confers 23S rRNA site
dulation
E mutations introduces binding site modulation. Noted efﬂux via mmpL5
ss-resistance with Clofazimine)
tation of reductive activating Rv3547 gene
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Mtb infection begins upon pulmonary exposure, following inhala-
tion of active bacilli from the surrounding environment. The risk of
being infected is greatly inﬂuenced by many factors, most of which
stem from living and working conditions. Population density, weather,
duration, and intensity of exposure to the Mtb (cramped living and
work environments with poor ventilation), a set of virulence factors
unique to the infecting organism, and relative immunocompetency of
the would-be host are all variables associated with succumbing to an
Mtb infection.
Initial infection occurs when a carrier exposes Mtb to the air via
coughing. Small droplets are expelled from the lungs that contain a
small number of individual organisms (b10) that must be inhaled
deep into the lungs. At this point host macrophages in the lung attempt
to phagocytize the pathogen (Fig. 3A) and transport it across the alveo-
lar epithelium and into the lung. This triggers a proinﬂammatory re-
sponse that will recruit other immune cells to form an encapsulated
granuloma, which is a typical immune response to a pathogen. At this
point, most of the bacterial burden is contained inside what are now
considered foamy macrophages (Fig. 3B), which begin to line the out-
side of the granuloma. When the granuloma is ﬁrst formed, it is well
vascularized and a lot of immune cells are present (Fig. 3C), which bol-
sters the ability of drugs to reach the infection and the host's immune
system to combat the pathogen. As the granuloma continues to mature
against the relentless immune response, the outerwall begins to harden
with a thick ﬁbrous capsule, and the inner core is walled-off from the
immune cells. Foamy macrophages line the outside of this lesion, cells
die and caseum develops at the core, which cuts off the remaining vas-
culature. At this point, the granuloma is considered necrotic, and the ba-
cilli exist extracellularly in this caseum and can enter their largely
dormant state (Fig. 3D). Necrotic granuloma lesions (also known as tu-
bercles) make drug penetration difﬁcult and render mouse infection
models that do not recapitulate this complex pathology poor surrogates
for the human disease. After years or in cases of immune system com-
promise, the granulomas will fuse to the airways of the lungs and
burst, releasing the pathogen to spread to new tissue and new hosts
(Fig. 3E) [22]. Each of these points in the Mtb life cycle have different
microenvironments that can affect drug susceptibility. For example, var-
ious degrees of vasculature result in lower bloodﬂow, decreased oxygen
levels, and pH differences in the intra/extracellular ﬂuids that can affectA B C
Fig. 3. Simpliﬁed depictionionization or activation of drugs, drug targets in Mtb may be turned off,
depending on the replication stage (latent vs. actively replicating), and
the ability of the drug to penetrate tissues and membranes required to
reach the mycobacteria.
2. Drugs under development
The past few years have seen the ﬁrst approvals of new antitubercu-
lar drugs in more than 50 years, in large part due to coordinated efforts
of government programs, nongovernmental organizations, and support
from pharmaceutical companies. In addition to these new chemical
entities available in the clinic, there is a host of small molecules in the
development pipeline and at the late-discovery stage. The Stop TB Part-
nership has been instrumental in organizing information, consolidating
clinical andpreclinical data, and raising awareness aboutMDR-TB emer-
gence. The Partnership offers an up-to-date list of agents that are in the
pipeline and currently undergoing clinical trials, along with links to rel-
evant publications and research information (Fig. 4; www.newtbdrugs.
org). However, the development of some drugs in this pipeline appears
slow and even stalled, a phenomena attributed to various ﬂaws the clin-
ical candidates possess that have been discussed at length in other re-
views [5]. The paucity of agents in Phase I is also a concern, which is
not indicative of a healthy pipeline, as many compounds are needed at
this stage to combat usual failure rates as compounds advance through
clinical trials.
2.1. Diarylquinolones and respiratory chain antagonists
The diarylquinolones are the most advanced series of novel antitu-
bercular drugs. The recently approved bedaquiline falls under this clas-
siﬁcation. Bedaquiline is highly selective and speciﬁcally inhibits
essential ATP synthase activity in replicating and dormantmycobacteria
but not in other prokaryotic or eukaryotic cells [23,24]. Through the
growth of drug-resistant mutants, it was discovered that the rotor ring
of the organism's F0F1 ATP synthase was the target, speciﬁcally binding
to the c subunit [25]. Mtb survives in a nonreplicating state using a pool
of ATP that is used tomaintain an energizedmembrane produced by the
F0F1 ATP synthase [26]. This makes bedaquiline a primeweapon for kill-
ing the latent Mtb subpopulation. With a mechanism of action distinct
fromRIF and INH, bedaquiline is an effective addition to anMDR-TB reg-
imen. Discovered during a phenotypic screen performed by Janssen,D E
of the Mtb lifecylce.
Pre-Clinical
•CPZEN-45
Phase I
•TBA-354
•Nitroimidazole
•Q203
•Imidazopyridine
•Caprazene nucleoside
•Lee1599
•Spectinamide
•SQ641
•Macrolide
•PBTZ 169
•Benzothiazinone
•BTZ 043
•Benzothiazinone
•Capuramycin •Rifapentine
Phase II
•Sutezolid
•AZD5847
•SQ109
Pyrazinamide
•Levofloxacin with
OBR(MDR-TB)
Phase III
•Bedaquiline*withOBR
(MDR-TB)
•Delamanid*withOBR
(MDR-TB)
•Pretomanid-Moxifloxacin-
Pyrazinamide
•SEQ-9
•Bedaquiline*-Pretomanid-
Fig. 4. Drugs that hold clinical promise that are in development and testing. Pipeline info from www.newtbdrugs.org *conditionally approved agents.
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resistant isolates, with a minimum inhibitory concentration (MIC) of
0.03 μg/mL for drug-sensitive Mtb and 0.12 μg/mL for drug-resistant
strains, aswell as outstanding activity in in vivomurinemodels. Howev-
er, bedaquiline's efﬁcacy in mice has not been as pronounced in
humans, presumably due to limited distributionwithin humangranulo-
mas. Bedaquiline is a large lipophilic drug that is subject to CYP3A4me-
tabolism and has been noted to have PK drug–drug interactions with
the CYP3A4 inducer RIF, which decreases its activity [27]. Bedaquiline
has been associated with QT-prolongation and must be carefully com-
bined with other drugs that share this risk, including ﬂuoroquinolones,
macrolides, clofazimine, or drugs that inhibit CYP3A4, which may in-
crease its exposure [15]. Thus, efforts are ongoing to develop second-
generation diarylquinolones that will improve the drug's physiochemi-
cal properties and remove its cardiac liability. This effort has been re-
cently aided by the co-crystal structure of bedaquiline bound to its
active site in the ATP synthase, which should enable structure-guided
design of more potent and less toxic analogs [28].
At the time of this writing, Q203 (Fig. 5), an imidazopyridine antitu-
bercular compound that also acts on the respiratory chain, just entered
Phase I clinical trials. Q203 targets the cytochrome b subunit (QcrB) of
the cytochrome bc1 complex. This complex is an essential component
of the respiratory electron transport chain of ATP synthesis. Q203 causes
a rapid depletion of intracellular ATP at an IC50 of 1.1 nM and interruptsFig. 5. Q203, which is currently in phase I clinical trials, has robust activity against latent
Mtb and is a promising option for addition to MDR-TB treatment regimens.ATP homeostasis in dormant Mtb at an IC50 of 10 nM. Both of these
values are better than bedaquiline's measures, and they explain
Q203's excellent killing proﬁle in chronic Mtb infection models. Spon-
sored by Qurient Therapeutics (Gyeonggi-do, Korea), Q203 was discov-
ered after medicinal chemistry optimization and a high-throughput
screen (HTS) performed against infected human macrophages [29].
This screen identiﬁed 96 compounds that were able to perfuse and ac-
cumulate enough in themacrophage to display dose-dependent growth
inhibition. The imidazopyridine scaffold was selected due to its activity
in both macrophages and free media, and the initial hit was active
against clinical MDR-TB isolates [29]. After the initial hits were evaluat-
ed, 477 analogs were synthesized, aided by structure-guided design,
and the best was Q203, with an MIC50 of 2.7 nM in broth media and
0.28 nM inside the macrophage. Kim et al. reported PK and safety-
proﬁle data compatible with once daily oral dosing, with 90% oral bio-
availability in mice, and a half-life of almost 24 h. There was no detec-
tion of cytotoxicity in vitro or in vivo, no signs of hERG inhibition
(indicative of limited cardiotoxicity), and mice tolerated 1 g/kg doses
for 2 weeks. Q203 did not inhibit any P450 isoforms and was not a sub-
strate or inhibitor of P-gP efﬂux,which indicated a low risk of drug–drug
interactions. Though it should be noted that like bedaquiline, Q203 is a
highly lipophilic drug,with very high serumprotein binding. ThePhase I
clinical trial (clinicaltrials.gov identiﬁer: NCT02530710) enrolling
healthy patients is a dose-escalation study starting at 100 mg dosing
that will be adjusted based on PK analysis. Further combination trials
will be needed to determine whether Q203 can function synergistically
in combination with other second-line agents to treat MDR-TB which
are no longer susceptible to INH or RIF, in the hopes of shortening the
duration of therapy compared to current treatments for MDR-TB.
The imidazopyridine QcrB inhibitors [30] were discovered
around the same time by several groups applying phenotypic MIC
screening approaches of pharmaceutical company screening collec-
tions. The imidazopyridine core is widely distributed in pharmaceu-
tical compound screening collections as the core is found in many γ-
aminobutyric acid (GABA) receptor agonists, including the sleep aid
60 D.T. Hoagland et al. / Advanced Drug Delivery Reviews 102 (2016) 55–72ambien. Miller et al. used an anagram approach to add structural diver-
sity to adjust the imidazo[1,2-a]pyrimidine core to obtain enhanced
Mtb activity and remove human GABA receptor activity [31]. By simply
rearranging functional groups already present on ambien, the investiga-
tors increased the mycobacterial activity 2500 fold (ambien: 10 μM➔
ambien “anagram”: 4 nM) and maintaining good safety. The best com-
pounds were cross-resistant with Q203, thereby conﬁrming a similar
mechanism of action. The differential display of side groups in this se-
ries offers the advantage of providing compounds with alternative PK
and ADME properties compared to those of Q203. This is a nice example
of scaffold development to provide an additional pool of Mtb drug
candidates, though at this time, these molecules are best described as
backup candidates.
2.2. DprE1 inhibitors
Decaprenylphosphoryl-β-D-ribose 2′-epimerase 1 (DprE1) was ﬁrst
identiﬁed as the target of 1,3-benzothiazin-4-ones (benzothiazones),
which are potent antimycobacterial agents. DprE1, in combination
with DprE2, catalyzes the epimerization of decaprenylphosphoryl-β-D-
ribose to the corresponding of decaprenylphosphoryl-β-D-arabinose
[32], thereby providing a crucial precursor to the cell wall
arabinogalactan polysaccharide via a series of sequential oxidation–
reduction reactions [33]. This target is frequently identiﬁed as the
mechanism of action of hits identiﬁed in whole-cell phenotypic MIC
screens, most likely due to its key biosynthetic role, high metabolic
turnover, presence of nucleophilic residues at its active site, and loca-
tion on the extracellular face of the cytoplasmic membrane that does
not require transport inside themycobacterium [34]. As an essential as-
pect of Mtb survival and a novel mechanism of antitubercular activity,
optimized DprE1 inhibitors are thought of as powerful new classes for
the treatment of MDR-TB, with limited cross-resistance to current ther-
apeutic options [35]. There is a host of promising hits being investigated
currently, but in this review, we will focus on those that are furthest
advanced.
The benzothiazones have displayed nanomolar Mtb activity in mul-
tiplemodels, including ex vivo and in vivomurinemodels [36]. PBTZ 169
(Fig. 6) is the lead molecule in this series and is being developed by the
Innovative Medicines for Tuberculosis (Lausanne, Switzerland). Both
PBTZ 169 and a backup benzothiazone BTZ 043 are being studied
preclinically. PBTZ 169 has the advantage of being slightly more potent
and not being stereoselective, meaning it is generated via an easier and
cheaper synthesis process [37]. The benzothiazones are irreversible in-
hibitors that require activation of an aromatic nitro group for antituber-
cular activity. The nitro group is required, as well as a meta electron–
withdrawing group, typically either a triﬂuoro methyl or another nitro
(dinitro benzenes). The nitroaromatic group is available for a speciﬁc
Mtb mediated bioreduction to a corresponding reactive nitrosoarene.
The nitroso group then reacts with an active site cysteine residue inFig. 6. PBTZ 169 and BTZ 043 with the covthe DprE1 enzyme to form a semimercaptal adduct inactivating the en-
zyme [38]. Importantly, human reductivemetabolismdoes not have the
ability to activate this prodrug series providing a suitable safetywindow
and are negative in the Ames test for DNA mutagenesis.
A single mutation to the Cys387 residue is the commonly associated
resistance mechanism and results in more than a 500-fold reduction in
benzothiazone activity. Delamanid is similarly reduced by Mtb to elicit
its bactericidal properties but does not result in cross-resistance with
the benzothiazones as they are bio-reduced by a different enzyme
(F420-deazaﬂavin–dependent nitroreductase [39]).
An alternative class of DprE1 inhibitors, the 1,4-azaindoles (Fig. 7),
were identiﬁed via a scaffold-morphing approach by AstraZeneca (Wal-
tham,MA) and now are being advanced by the Global TB alliance (New
York, NY). These compounds were derived from an imidazopyridine
HTS hit that displayed a good Mtb MIC but were not bactericidal. To
gain bactericidal activity, multiple scaffold morphs were performed.
The resulting 1,4-azaindole scaffold underwent several structure–
activity relationship (SAR) optimizations to improve bactericidal activi-
ty, shift selectivity away from the human phosphodiesterase 6 (PDE6)
and increasemetabolic stability [40,41]. PDE6 is a key off target pharma-
cology for this class as it is expressed in rod and conephotoreceptor cells
of the eye, and extended inhibition can be detrimental to visual acuity. A
similar adverse event is noted with prolonged EMB exposure [42]. Lead
molecules from these optimizations have amarked decrease in PDE6 in-
hibition (N100 μM) and a good PK proﬁle, whilemaintaining or improv-
ing Mtb activity. This class of DprE1 inhibitors (at 100 mg/kg) had
comparable efﬁcacy to INH in a murine model of acute TB infection
and to RIF in a chronic model in vivo [41]. An important distinction for
this potential drug class is the lack of cross-resistance with the
benzothiazones, despite having the same molecular target. This is due
to the noncovalent nature of inhibition the 1,4-azaindoles display. The
commonly associated resistance mutation for benzothiazones is the
single-point mutation of the nucleophilic Cys387, which does not affect
the binding of the 1,4-azaindoles, nor their antitubercular activity [40].
TCA1 (Fig. 8), a member of a third class of promising DprE1 inhibi-
tors, was discovered using a clever screen aimed at ﬁnding inhibitors
that prevent mycobacterial bioﬁlm formation. TCA1 has bactericidal ac-
tivity against wild-type TB and MDR-TB in both active and dormant
states and is effective in both acute and chronic in vivo infection models
[43]. TCA1 not only has activity under normal growth conditions and
bioﬁlm culture conditions but also has the ability to prevent bioﬁlm for-
mation. With a narrow spectrum of activity speciﬁc to mycobacterium,
TCA1 displayedpotent bactericidal activity against XDR-TB, suggesting a
novel mechanism and a great potential to be optimized into a new ther-
apeutic option for MDR-TB. Using puriﬁed DprE1 enzyme, it was shown
that TCA1 prevents the formation of DPA in a dose-dependent manner.
Results from a competitive binding assay also showed that TCA1 binds
at the same site as the benzothiazone, but there does not appear to be
cross-resistance associated with either's resistant mutants [43]. Thesealent inhibition mechanism of DprE1.
Fig. 7. The 1,4 azaindoles are a promising class of novel DprE1 inhibitors that are reversible
and orally bioavailable.
Fig. 9.MmpL3 inhibitors exhibit structural diversity.
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DprE1, which conﬁrmed a signiﬁcant overlap in the binding domains.
One key difference to be noted is that the benzothiazones do not display
activity in latent Mtb cells, and TCA1 down regulates the expression of
genes associated with persistence (i.e., fdxA, a low-redox electron carri-
er [44]) and drug tolerance. This added beneﬁt of killing latent Mtb is
thought to bedue to a second target of TCA1, a target that is not essential
for growth in optimal conditions but is physiologically relevant when
themycobacterium is under antibiotic stress. This was shown in a series
of growthmodels usingDprE1 overexpression and various nutrient-rich
or nutrient-depleted media [43]. In a competitive molecular pull-down
experiment using a TCA1 analog, it was determined thatMoeWwas the
secondary target. MoeW is a protein involved in molybdenum cofactor
biosynthesis, and the gene encoding this protein is conserved only in
Mtb and not in any other mycobacterium or bacterial species. The mo-
lybdenum cofactor is essential for nitroreductase activity in Mtb,
which is important for the hypoxic and nitric oxide–induced stress
response.
2.3. MmpL3 inhibitors
The Mycobacterial membrane protein Large (MmpL) family of ex-
port proteins are involved in transportation of metabolites from the cy-
tosol ofMtb. TheMtb genome contains 12 genes that express theMmpL
proteins that are considered resistance-nodulation-division proteins,
which play an important role in Mtb survival and pathogenesis [45].
MmpL3 is required for the export of mycolic acids in the form of treha-
lose monomycolates to the periplasmic space or outer membrane.
Established as the only protein in this family that is essential for myco-
bacterial survival, MmpL3 is an attractive drug target. It is an important
membrane protein, and a very common target elucidated in hits from
whole-cell phenotypic assays, similar to DprE1 and QcrB [34]. Because
MmpL3 is an easily druggable target with proven essential roles in
Mtb survival, there is immense interest in MmpL3 inhibition as a
novel mechanism of action for a new antitubercular agent.
The most advanced MmpL3 inhibitor is SQ109 (Fig. 9), a structural
derivative of EMB's diaminemoiety [46]. The initial effort in discovering
SQ109 was undertaken using a combinatorial chemistry approach to
ﬁnd an EMB analog with improved activity because EMB is the weakest
agent of the frontline therapeutics. However, retrospective analysis
using SQ109-resistant mutants showed that this inhibitor's mode ofFig. 8. TCA1 is a recently identiﬁed DprE1 inhibitor with activity against latent MDR-TB
infection in vivo.action differs from EMB, with action associated with MmpL3 inhibition
(Fig. 9). It is now accepted that SQ109 has polypharmacology proper-
ties, as it has activity on fungi and bacteria that do not possess mycolic
acids [47,48] and activity against latent cells that do not require active
cell wall synthesis [49,50]. Further investigation of SQ109's mechanism
of action divulged additional inhibition of menaquinone synthesis, cel-
lular respiration, and ATP synthesis in part due to dissipation of the pro-
tonmotive force across the cytoplasmic membrane [50]. These multiple
mechanisms of antitubercular activities suggest that SQ109would be an
effective agent to add to MDR-TB therapies and will cause limited in-
stances of resistance if used in such a regimen, though it does have
some pharmacological limitations due to its amphipathic structure.
More speciﬁc classes of MmpL3 inhibitors were discovered via a
whole-cell phenotypic screen performed at the Novartis Institute for
Tropical Diseases (NITD; Singapore). Indolcarboxamides (Fig. 9) that
have excellent PD properties, including potent bactericidal activity, dis-
play both concentration and time-dependent killing [51]. Lead mole-
cules are orally bioavailable and display limited toxicity, including no
inhibition of HepG2, hERG, AMES, or CYP450. They possess a narrow
spectrum of activity against Gram-positive and -negative bacteria, a
positive attribute for a potential antitubercular agent. Researchers
working with indolcarboxamide-resistant Mtb discovered no cross-
resistance associatedwith any commonly used drugs forMtb treatment.
Cross-resistance was noted with other MmpL3 inhibitors, including
SQ109 (16-fold shift in MIC), AU1235 (N1024-fold), and BM212 (2-
fold) [52]. This range of MIC shifts can be explained by different binding
sites of the inhibitors in MmpL3. One crucial advantage that the
indolcarboxamides display is a dramatic accumulation in the lungs
in vivo. Early analogs of the initial HTS hit showed a 5-fold higher Cmax
and a 10-fold increase in AUC0–24 h, in respect to lung concentrations
vs. plasma concentrations of drug [52]. In general, MmpL3 inhibitors
are quite lipophilic, which is not surprising, given the role of MmpL3
in exporting mycolic acids. This lipophilic nature, in turn, causes prob-
lems with distribution and propensity for oxidative metabolism of the
inhibitors.
2.4. InhA inhibitors
Isoniazid is a staple of frontline tuberculosis therapy. Its molecular
target is the mycobacterial enoyl reductase InhA, which is required for
the biosynthesis of mycolic acids, the dominant feature of the lipophilic
Fig. 11. Direct InhA inhibitors that are under development by GSK and the NITD.
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[53,54]. There are two distinct fatty acid biosynthesis (FAS) routes;
mammals rely on the FAS I pathway, and bacteria rely on the FAS II.
Mycobacteria contain both pathways, with a distinct subset of enzymes
included in FAS II for the biosynthesis of extraordinarily long mycolic
acids. These FASII enzymes are where drugs can be designed for myco-
bacterium speciﬁcity, an important consideration for the development
of a therapy for MDR-TB. INH is a prodrug that requires activation by
the catalase–peroxidase KatG to inhibit InhA, and this bioactivation
step is where Mtb primarily develops resistance by inactivating this
nonessential enzyme (Fig. 10). Therefore, new prodrugs targeting
MDR-TB would run the risk of encountering cross-resistance in cases
of Mtb if their bioactivation pathway is similar to that of INH or other
prodrugs that are currently used in TB therapy, including EMB and
PZA. The resulting INH–NAD adduct inhibits the enzyme and displays
remarkable residency time due, in part, to a conformational shift in
helix 6 that occurs after the initial binding, a shift that does not occur
with rapid reversible inhibitors of InhA [55–57]. Peter Tonge and others
have stressed the importance of residency time in drug discovery and
lead optimization [58–60]. Just having tight binding afﬁnity is not
enough. Typically, it is the dissociation rate of the inhibitor from the
enzyme that is more indicative of the biological activity in vivo [61].
FabI, the S. aureus ortholog of InhA, has been the subject of much anti-
bacterial structure–based drug design, with at least two candidates ad-
vancing into clinical trials (NCT02426918) [62,63]. This information
provides a useful knowledge base for ongoing efforts to discover
direct-acting inhibitors of InhA that are not susceptible to KatG-
associated cross-resistance.
Researchers at GSK (Middlesex, UK) and subsequently AstraZeneca
have produced lead molecules with a methyl thiazole core (Fig. 11)
that are nanomolar InhA inhibitors. Both have excellent MIC values
against Mtb [64,65] and display a favorable preclinical toxicity proﬁle,
with limited CYP450 activity and favorable preliminary PK properties.
The GSK lead has a whole-cell MIC of 1 μM and an intracellular MIC of
0.48 μM. However, the series falls short of INH in vivo potency and re-
quires more optimization to be clinically relevant. The NITD recently
published a thorough study of another chemical class to directly inhibit
InhA, the 4-hydroxy-2-pyridones (Fig. 11) [66]. This class of orally ac-
tive compounds, the lead of which is NITD-916, displays potent bacteri-
cidal activity against multiple INH-resistant strains of Mtb and in vivo
efﬁcacy in acute- and chronic-infection models. The primary concerns
with this class of inhibitors are similar to those associated with the
MmpL3 series (i.e., activity against dormant bacteria and high lipophi-
licity) and poor resultant physiochemical properties of inhibitors that
engage mycolic acid–binding sites.
2.5. Novel β-lactam combinations
The β-lactams are the most populous class of antibiotics and are the
mainstay ofmost antibacterial drug treatment regimens; however, their
efﬁcacy against Mtb has always been limited. With the pressing
situation of the advance of MDR-TB and a greater knowledge of theFig. 10. INH bioactivation of the NAD adducmechanisms that render Mtb insensitive to β-lactams, efforts have
been renewed to determinewhether β-lactam agents can be developed
to treat MDR-TB [67]. Case reports of amoxicillin plus clavulanate have
shown some limited success treating MDR-TB [68,69]. However,
carbapenems are the most suitable β-lactams for treating Mtb as they
potently target the high-molecular-weight penicillin-binding proteins,
and also inactivate the unusual ι,D-transpeptidases that form the 3➔3
crosslinks found in the unique Mtb cell wall [70]. Additionally,
carbapenem are less favorable substrates for the Mtb β-lactamase
BlaC, which is expressed at high levels and inactivates most other β-
lactams. Meropenem and imipenem have been tested for MDR-TB, in
combination with a β-lactamase inhibitor, such as clavulanate, which
inactives BlaC [69,71–73]. Clinical efﬁcacy has been demonstrated in
XDR-TB by using meropenem–clavulanate combinations, which
requires administration three times daily via infusion [74,75]. One
advantage the β-lactams offer as a series over other second-line
alternatives is that they have a well-deﬁned safety proﬁle [76].
However, complications with the use of these powerful broad-
spectrum antibiotics in a long-term course of therapy can originate
with disturbances of the patients' microbiome and could lead to
regiment compliance issues.
Faropenem (Fig. 12), a penem, is structurally similar to the carba-
penems. The penem ring system is slightly less strained and conse-
quently has improved chemical stability and has been modiﬁed to a
prodrug ester (faropenem medoxomil) that allows for oral administra-
tion, both desirable advantages for treatingMDR-TB [77,78]. Already ap-
proved for treatment of respiratory infections in humans, faropenem
has displayed promising bactericidal activity in both active and non-
growing, metabolically active Mtb cells [79], which is comparable to
that seen with meropenem. Such results combined with renewed ef-
forts to design a new generation of Mtb-targeted β-lactams, especially
in conjunction with recent advances in β-lactamase inhibitor design,
hold promise for clinical development as MDR-TB therapies. The
primary limitations of this class of inhibitors relate to issues of obtaining
sufﬁcient drug exposure, for instance meropenem's dosing regimen
requires 1g infusions, three times daily.t that is responsible for InhA inhibition.
Fig. 12. Faropenem, a β-lactam antibiotic used in pulmonary infections that may soon be
used in MDR-TB regimen.
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Linezolid, the ﬁrst-in-class oxazolidinone antibacterial agent, has
demonstrated excellent clinical efﬁcacy in treating drug-resistant
Gram-positive pulmonary infections. Oxazolidinones are protein syn-
thesis inhibitors that bind to the 50s ribosomal subunit of the 23S
rRNA. Linezolid possesses robust efﬁcacy in treatingMDR-TB infections,
despite havingmodest activity in vitro and inmouse models of acute TB
infection [80]. These results have encouraged further examination of the
oxazolidinones class of antibiotics for the treatment ofMDR-TB [80–84].
Only two agents are currently clinically approved, linezolid and
tedizolid, but expansive efforts have been made to develop next-
generation oxazolidinones that have greater antibacterial potency and
less adverse effects. For other indications, linezolid use is generally re-
stricted to less than 2weeks, because the agent can causemyelotoxicity
(as a result of mitochondrial protein synthesis inhibition), cytopenia,
neuropathies, lactic acidosis, and rhabdomyolysis. This is particularly
troublesome when undergoing prolonged therapy that is required for
MDR-TB. Avoiding these mechanistic toxicities is a top priority in the
design of future analogs. Over the past decade, many oxazolidinone an-
alogs have been created in antibacterial-discovery programs at major
pharmaceutical companies, some of which are pharmacologically vali-
dated leads that arewell suited for repurposing forMDR-TB applications
with larger safety indices. Sutezolid (Fig. 13) has emerged as a promis-
ing example and has completed a Phase II clinical trial (NCT01225640).
In addition, AstraZeneca is pursuing a second-generation oxazolidinone
AZD5847 that also displays promising efﬁcacy in animal models in a
Phase II clinical trials [85] (NCT01516203).
Sanoﬁ (Paris, France) has recently begun to reinvestigate macrolide
antibiotics from their compound archive for MDR-TB application be-
cause of the efﬁcacy of other protein synthesis inhibitors and the report-
ed use of the macrolide clarithromycin. From the natural product
sequanamycin A (SEQ-503), chemical optimization has obtained SEQ-
9 (Fig. 14). SEQ-9 has better mycobacterial potency and much better
PK properties, including increased plasma stability, a better metabolic
proﬁle (high stability and no CYP inhibition), and it is efﬁcacious in
acute in vivomurine models. SEQ-9 does not appear to be bactericidal
yet, it has notable activity against replicating Mtb, latent Mtb, and
intramacrophage Mtb displaying submicromolar MIC80 activity in all
three models. An exciting aspect of SEQ-9 is that there is no MIC shift
in multiple lines of human clinical Mtb isolates and does not appear toFig. 13. Second-generation oxalidinones designed to combat MDR-TB pulmonary
infections with fewer adverse events than their parent compound linezolid.be hampered by inducible macrolide mediated resistance that restricts
the use of other macrolides [86]. When Sanoﬁ researchers added SEQ-
9 to combination studies, they noted a dramatic increase in the total
bactericidal activity of those combinations. The greatest increase was
observed in combination with bedaquiline and PA-824, with nearly
complete elimination of chronic TB infection in mice by 8 weeks.
There is still plenty of optimization to be performed on this macrolide,
but this study adds more evidence that adding a protein-synthesis
inhibitor to an antitubercular regimen could dramatically reduce
treatment duration. Othermacrolides are being investigated and should
produce additional options to MDR-TB treatment.
Leucyl-tRNA synthase (LeuRS) is an attractive antibiotic target that is
required for protein synthesis. A unique class of boron-containing inhib-
itors has been identiﬁed that act on the editing site of LeuRS and disrupt
its proofreading role in leucyl-tRNA synthesis. These inhibitors trap
tRNA of the LeuRS away from the active site to a separate editing site,
approximately 30 Å away [87]. Locking this terminal ribonucleotide
via covalent attachment of the ribosyl diols to the boron atom
(Fig. 15) blocking the tRNA from being properly aminoacylated and
preventing protein synthesis. Recently, this inhibitor class has produced
an approved agent for fungal infections [87] and late-stage clinical can-
didates for the treatment of Gram-negative infections [88,89]. Anacor
Pharmacueticals (Palo Alto, CA) in collaboration with GSK recently
opened new investigations to identify oxaboroles that are active against
Mtb identifying a promising Mtb selective subclass. These low molecu-
lar weight and hydrophilic inhibitors have notably good oral bioavail-
ability and PK properties. The LeuRS editing site is structurally unique
across species, which enables scientists to develop species-speciﬁc in-
hibitors [88]. Anacor Pharmaceuticals is now optimizing this series of
Mtb LeuRS–speciﬁc protein-synthesis inhibitors. This class of agents
has been described to the StopTB Partnership as having potent, Mtb-
speciﬁc activity in both acute- and chronic-infection murine models
in vivo at very low doses (b10 mg/kg per day).
2.7. Rekindling old antibiotics with natural product chemistry
The ﬁrst effective treatment for TB followed the isolation of strepto-
mycin in 1943 and its clinical introduction in 1946. Streptomycin was
ﬁrst isolated by Albert Schatz, a graduate student in SelmanWaksman's
laboratory at Rutgers University (New Brunswick, NJ). The antibiotic
was isolated from the bacterial species from which its name is derived,
Streptomyces griseus. This discovery was the genesis of studying natural
products produced by bacteria rather than those produced by plants or
fungi. This discovery method of screening soil-derived microbes for
antibiotic production helped launch the “Golden Age” of antibioticFig. 14. SEQ-9, a macrolide antitubercular agent derived from a natural extract from
Allokutzaneria albata.
Fig. 15.Mechanism of action for a representative oxaborole LeuRS inhibitor.
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otics were discovered [90]. The most important application of this
approach in the area of TB therapy was the discovery of rifamycin anti-
biotics by Piero Sensi at Lepetit Pharmaceuticals research laboratory in
Milan, Italy. Semisynthetic modiﬁcation of rifamycin produced rifampi-
cin, which remains one of the most effective antitubercular agents ever
developed. In the course of soil-microbe screening efforts, many potent
series were left behind due to chemical instability, rapid metabolism,
toxicity, or an undesirable spectrum of activity. However, with the rise
of antibiotic resistance, there has been an increased interest in
reinvestigating some of the scaffolds that have displayed a unique
mechanism of action or where new structural or mechanistic target in-
formation can be exploited. As the last group of TB drugs under develop-
ment to be discussed in this review, we will focus on some synthetic
adaptations made to underexploited natural product entities that have
the potential to be adapted to clinically relevant drug classes for the
treatment of MDR-TB.
Spectinamides are semisynthetic derivatives of the antibiotic specti-
nomycin produced by Streptomyces spectabilis. Spectinomycin works by
inhibiting ribosomal translocation and consequent protein synthesis by
binding to a unique binding site on the 16S ribosomal subunit [91,92]. A
second-line agent used in the treatment of gonorrhea infections, specti-
nomycin has a documented excellent safety proﬁle, with no associated
nephrotoxicity or ototoxicity, which are common adverse effects of
aminoglycosides, consistentwith its distinctmechanismof action.How-
ever, spectinomycin only has modest antitubercular activity. Using
structure-guided design, workers in the Lee laboratory generated a
novel series of spectinamide analogs, including lead 1599 (Fig. 16),
that have greatly increased antitubercular activity (spectinomycin Mtb
MIC =50 μg/mL ➔1599, 0.8 μg/mL). Structural modiﬁcations in the
amide side chain enable the spectinamides to escape an intrinsic efﬂux
mechanism through the Rv1258c pump that limits the activity of spec-
tinomycin against Mtb [93]. Spectinamides are highly selective for Mtb,
display a marked postantibiotic effect, and lack cross-resistance with
any other protein-synthesis inhibitors, and retained activity against
MDR-TB and XDR-TB. 1599 is active in mouse models of acute and
chronic TB infection and demonstrates synergy in vivowhen combined
with RIF and PZA and additivity when combined with second-line
agents used for treating MDR-TB suggesting they are good potential
partners agents for novel treatment regimens. The hydrophilic nature,
low protein binding, lack of hepatic metabolism, and ability to avoidFig. 16. Lee 1599, an optimized spectinomycin analog that possesses high selectivity for
bacterial RNA and escapes efﬂux pump Rv1258c.efﬂux also makes them favorable combination partners, though this
series is limited by their lack of oral bioavailability.
Griselmycins are Streptomyces-derived antibiotic class that have
been recently re-explored to generate new agents to treat MDR-TB.
Griselimycin (Fig. 17) was discovered in the 1960s at which time its an-
titubercular potency was noted by Sanoﬁ but as it possessed poor PK
properties it was eventually dropped in favor of other programs due
to their rapid elimination following oral administration [94,95]. Sanoﬁ
recently reinvestigated the griselmycin scaffold, generating several ana-
logs of the cyclic peptide by total synthesis, which appears to have im-
proved therapeutic potential. Most interestingly, the investigators
identiﬁed the molecular target as the DNA-polymerase sliding clamp
DnaN, validating it as a novel target for future drug discovery [96]. In
this study, analogs of griselimycin were synthesized by structure-
guided design, with the hopes of increasing metabolic stability and
maintaining in vitro and in vivo efﬁcacy. A cyclohexyl analog proved to
be efﬁcacious and blocked the primary point ofmetabolism by sterically
limiting access to cleavage of the Proline-8 amide bond. Of note, this
preclinical class showed a low emergence of spontaneous-resistance
mutations, even those that arise at a drastic ﬁtness cost to the
mycobacteria. The primary resistance mechanism identiﬁed is the am-
pliﬁcation of the dnaN gene, but any mutants with such a mutation
grew markedly slower [96]. This highly disfavored, rarely occurring re-
sistance risk, coupled with a novel mechanism of action and promising
oral PK properties, have propelled this class of naturally derived antitu-
bercular compounds into the upper echelon of preclinical leads for
MDR-TB.
Capuramycin is a naturally occurring antibiotic secreted by
S. griseus around which much antibiotic chemistry has been performed.
Capuramycin inhibits peptidoglycan biosynthesis by targeting translocase
I, an essential enzyme in this pathway and a distinct target from others
discussed in this review [97]. Many capuramycin derivatives have
been synthetically generated and subclasses identiﬁed that show im-
pressive antimycobacterial potency and selectivity, but also commonly
suffer from poor aqueous solubility. However, they exhibit rapid bacte-
ricidal activity and a lengthy postantibiotic effect,making promising po-
tential additions to Mtb therapy. Daiichi–Sankyo (Parsippany, NJ)
created a library of more than 7000 capuramycin analogs, including
many that have potent antimycobacterial activity; the lead from this se-
ries is SQ641 (Fig. 18) [98,99]. Sequella (Rockville, MD) has licensed the
right to develop this compound though little progress has recently been
reported. As nucleoside-peptide antibiotics, capuramycins have limited
oral bioavailability and pharmaceutical properties, which limit their de-
velopment. To get around these limitations, Lilly (Indianapolis, IN) has
explored aerosol delivery of their capuramycin lead (CPZEN-45;
Fig. 18) with positive results [100]. This study shows that CPZEN-45 is
efﬁciently absorbed by lung tissue through inhalation and can reach
therapeutically relevant concentrations at the primary site of Mtb
infection opening the door to clinical trials.Fig. 17.Griselimycin scaffold. R position is hydrogenon thenatural product and cyclohexyl
on the orally available analog.
Fig. 19. Pyridomycin is a naturally occurring InhA inhibitor. Possessing the same
mechanism as known drugs lends credence to the importance of InhA as a drug target.
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pyridomyceticus (Fig 19). Recent studies by the Cole group demon-
strated that Pyridomycin is a direct inhibitor of InhA [101]. However,
in contrast to INH and ETH that also target InhA, pyridomycins do not
require bioactivation by KatG or EthA mitigating the primary potential
source of cross-resistance to these existing drugs. Structural studies
demonstrated that pyridomycin spans the active site of InhA, making
key hydrogen bonds at both the substrate and NADH binding sites
[102]. Another interesting aspect of pyridomycin is its ability for its ar-
omatic rings to intramolecularly π-stack, a feature that might aid in cel-
lular entry across the Mtb cell envelope. The drug is able to penetrate
host macrophages, displaying bacteriocidal activity at 10 μg/mL but is
inactive against slowly replicating bacteria consistent with its mode of
action against cell wall biosynthesis. The structural and the SAR knowl-
edge from other inhibitor programs available on InhA combined with
pyridomycins chemically tractable scaffold leave this natural product
ripe for synthetic derivatization. However, much work remains to
advance this molecule class into preclinical development.
3. Notable recent advances in drug discovery technologies for Mtb
As discovery and development of novel chemical entities to treat
Mtb has increased signiﬁcantly in recent years [50,103–105] so have
the technologies used to discover new agents. New technologies have
been developed to complement our increased understanding in the bi-
ology of the Mtb life cycle and the success and failures of prior drug de-
velopment strategies. While there is not space to adequately discuss all
these advances in this review, we do brieﬂy want to discuss the impact
of three key technologies—genomics, screening under deﬁned growth
conditions that recapitulate various microenviroments of the Mtb life
cycle, and MALDI-MS imaging of drug distribution within the infected
lung.
As discussed previously, the accessibility ofwhole-genome sequenc-
ing and genetic technologies that can be used tomodulate gene expres-
sion levels has revolutionized our understanding of Mtb. The ability to
search the genome for suitable therapeutic targets, to look for target
conservation across multiple strains and lineages of Mtb, and the ability
to compare tractability with similar targets in other bacteria now pro-
vide a rich pool of information at the start of any discovery programFig. 18. Two lead capuramycin analogs, SQ641 and CPZEN-45, that are currently
undergoing preclinical testing and optimizations.[21,106–109]. It is now typically required that any new target-based
drug discovery programs are ﬁrst validated by gene knockout and/or
gene knockdown experiments [110,111] to help ensure the druggability
of the target. These experiments give key insight into the sensitivity of
the Mtb cell to inhibition of a biochemical target, as it is clear that not
all therapeutic targets are created equal and inhibition of some are
more lethal than others.
The ability to screen Mtb under deﬁned growth conditions that bet-
ter represent the microenviroments of the Mtb life cycle is also an ad-
vancing technology in this ﬁeld displaying great promise [112]. A good
example is the high-throughput screening of macrophage-resident
Mtb that identiﬁed inhibitors active against cholesterol catabolism in
Mtb [113]. Mtb is an intracellular pathogen that infects and multiplies
in host macrophages, which is typically a very resource-deprived envi-
ronment. In this case, the pathogen must scavenge carbon sources
from the host, so Mtb has evolved speciﬁc catabolic enzymes to break
down substrates like cholesterol and particle remnants of low-density
lipids that are also scavenged by macrophages. Once inhibitors were
identiﬁed in themacrophage based screen, the researchers tested for in-
hibition of cholesterol catabolic pathway (or methyl citrate cycle) inhi-
bition by limiting the carbon source of in vitro grown cells in the
presence of the inhibitor. These studies led to novel inhibitors of
HsaAB, a two-component, ﬂavin-dependent hydroxylase that is crucial
to the degradation of the “A” ring of cholesterol [113]. While these in-
hibitors are still under development, they are best considered as chem-
ical probeswithwhich to study the role of cholesterol catabolism inMtb
infection. The Russell group's work is a landmark study because it has
identiﬁed and validated a new area of Mtb metabolism for chemother-
apeutic intervention and drug design.
Technology that enables us to detect and image drug distribution al-
lows researchers to gain a better understanding of howTB drugs distrib-
ute within the lungs of patients, and how this exposure compares to
rodent models of Mtb infection, is another signiﬁcant recent advance.
It is quite easy to look at a single parameter (e.g., plasma concentration)
and be deceived about howa drugwill act in a patient. However, plasma
concentration may be a poor indicator of tissue and granuloma perfu-
sion, especially perfusion into necrotic granulomas' caseum-ﬁlled
cores [114]. This phenomenon could help explain the failure of the
Rapid Evaluation of Moxiﬂoxacin in Tuberculosis (REMoxTB) clinical
trial, one of the largest Phase III TB trials ever conducted. The trial,
which included more than 1900 patients, was proposed to shorten
the duration of Mtb therapy from 6 to 4 months by substituting
moxiﬂoxacin for either INH or EMB. The trial was supported by results
from extensive combination testing in mice [115]; however, it was un-
able to conﬁrm the treatment shortening potential of moxiﬂoxacin
seen in mice. Subsequent data have shown that moxiﬂoxacin is not
able to fully penetrate human caseous lesions that have a low degree
of celluarity [114], despite showing high concentrations inside activated
macrophages [116,117].
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dependent drug concentrations in the Mtb-infected lung, taking advan-
tage of newMALDI-MS imaging technologies [116,118–121]. In a small
study of drug distribution in granulomas taken directly from the lungs
of MDR-TB patients who were treated with drug combinations at vary-
ing time points prior to lung resection, moxiﬂoxacin exhibited several-
fold lower concentrations in caseous regions of pulmonary lesions
compared to RIF, concentrating around the periphery of the lesion. RIF
exhibited a slow accumulation until high steady-state concentrations
were achieved deepwithin lesions, and PZAwas seen to rapidly perfuse
throughout the lesion. This inability to efﬁciently drug the entire lesion
probably explains why shortening the course of REMoxTB trail was not
successful. Theseﬁndings support a previous in vivo study in rabbits that
used similarmatrix-assisted laser-desorption/ionizationmass spectros-
copy imaging [122,123], effect. These results suggest that penetration
into caseous lesions is critical for future efforts towards treatment
shortening regimens (Fig. 20).Fig. 20. The various environments a drug must thr4. Discussion
There is an obvious need to continue the push to discover novel che-
motherapeutic options to treatMDR-TB infections. Resistance continues
to spread across the world, and an ever-expanding global population
and global strife will only serve to aid in this expansion. This review
has highlighted someof themore promising classes of agents developed
by various research groups, but this global effort must bemaintained to
ensure adequate weapons are available in this ever-evolving ﬁght. Ad-
vances in drug discovery approaches, technological tools, a better un-
derstanding of the mycobacterium biology and disease states, and
some hard learned lessons from failures in clinical trials have made
this paradigm appear more promising as of late. Thus, there is reason
to hope for improved outcomes for this serious disease are in the pipe-
line. In thepast decade, four primary strategies have been applied to dis-
cover the new agents discussed previously in this review: target-based
screening; phenotypic-based screening, semisynthetic natural productive in to be an effective antitubercular agent.
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Each of these approaches has its own advantages and disadvantages.
When the whole Mtb genome sequence became available in 1998
[124], it greatly aided the identiﬁcation of essential genes and facilitated
the recognition of many novel Mtb drug targets. This increased target
knowledge was thought to hold great potential and ushered in an era
of target-based drug discovery primarily through the use of high-
throughput screening (HTS). However, the HTS target-based approach
has to date only produced a few advanced leads with the current most
advanced compounds being the InhA inhibitor class discussed earlier
[125]. This mirrors the experience of the broader antibacterial drug dis-
covery community, though lessons in this regard were slower to be ac-
cepted in the Mtb ﬁeld. The primary limitations of this approach relate
to target selection, screening library composition, and the concomitant
hurdle of generating compounds that can penetrate and accumulate in
the Mtb bacilli and remain stable to human metabolism. To address
these limitations, there needs to be a better understanding of which
targets are suitable for this approach, chemical libraries need to be im-
proved upon and new approaches like fragment-based drug design
should be implemented, enabling the building out of high-afﬁnity
inhibitors with concomitant drug-like and Mtb penetrant properties
[126,127].
Once the difﬁculties of target-based approaches to TB drug discovery
became apparent, whole-cell MIC-driven HTS approaches dominated
this discovery space, efforts that were fueled by the discovery of
bedaquiline. This is in essence a reversion to an old approach that iden-
tiﬁed INH and EMB, but on amuch larger screening scale, taking advan-
tage of vast pharmaceutical screening libraries that have been put
together in the intervening decades. The primary advantages of this ap-
proach are as follows: it is not limited to inherent target bias, thus
allowing all potential chemically tractable targets to be explored simul-
taneously; common efﬂux and penetration issues are also addressed
along with target-sensitivity validation. After an active compound is
identiﬁed, resistantmutants can be generated and sequenced to identify
genetic variations and thus assist in deﬁning the mechanism of action.
The most common targets identiﬁed in Mtb via typical phenotypic
whole-cell screening were MmpL3, DprE1, and QcrB [30,105,128], all
of which have produced preclinical leads discussed earlier. Another ad-
vantage of this method includes the relatively low costs associated with
this approach. Many companies have legacy compound libraries can be
quickly repurposed for TB drug discovery, which can be compared to
published hit data sets for comparative purposes to identify novel
leads. Disadvantages include an often difﬁcult in vitro to in vivo active
transition; mitigating off target pharmacology as the hits are often de-
rived fromcompound classes generated for other humandisease indica-
tions; repeated discovery of compounds targeting the same enzymes
(MmpL3, DprE1, and QcrB); frequent discovery of prodrug activated
electrophiles, for which care must be taken to ensure these agents are
not activated by central human metabolism, though it must be noted
as evidenced by the nitroimidazoles, delaminid, and pretomanid this
is achievable. Finally, despite genomic evaluation of resistant mutants,
elucidating the molecular targets of drugs identiﬁed phenotypically
can be more complex, time consuming, expensive, and is generally
considered a bottleneck in this process.
These challenges are often compounded in lead optimization pro-
cess, as it is common to increase lipophilicity from the initial HTS hit
[129], and drug discovery in TB is no different. The NITD recommends
monitoring lipophilic efﬁciency to guide phenotypic-hit selection and
development, an opinion we share. Development of such compounds
will be a delicate balance of maintaining potency and optimizing expo-
sure via ADME (absorption, distribution, metabolism, and excretion)
properties. As shown in Fig. 21, there has been a trend in developing
new oral agents from phenotypic screening to better adhere to
Lipinski's rule of ﬁve, such as BTZ043, Azaindoles, and TCA1 [130,131].
However, it should be noted that most of the newer agents are still on
the high end of lipophilicity range (cLogP N 3). This not only makesformulation difﬁcult and increases the risk of drug–drug interactions
but may also play a role in limiting drug distribution into the caesum
microenviornment. The success of bedaquiline and delaminid are exam-
ples that high lipophillicity (cLogP values of 7.3 and 5.6, respectively)
can be overcome with advances in formulation to achieve proper oral-
exposure levels and advanced medicinal chemistry to block sites of ox-
idativemetabolism.However, they have had limited success in reducing
treatment duration, as in vitro and in vivo mouse efﬁcacy testing may
have suggested. The results of Q203 in clinical trials could addmore ev-
idence to the theory that these large lipophillic molecules have trouble
clearing mycobacterium from necrotic granulomas. The feasibility of
combining multiple high-liphophilic drugs in MDR-TB combination
therapywill likely need to be addressed. This is due to additive liabilities
and consequent drug–drug interactions causing decreased bioavailabil-
ity and additive toxicities. These complications, combined with the
more favorable distribution across multiple microenviornments, favor
the identiﬁcation and prioritization of phenotypic MIC screening hits
with more hydrophilic properties.
During the golden age of antibiotic discovery, many unique natural
product scaffolds were discarded in favor of compounds with more fa-
vorable characteristics, such as ease of production or lack of antibacteri-
al spectrum of activity. Recent efforts to optimize some of these
previously identiﬁed natural products for MDR-TB therapy, using a
semisynthetic chemical modiﬁcation approach has also proven highly
productive, yielding theMacrolide SEQ-9, Spectinamides, Griselimycins,
and Capuramycins, all of which are suitable to treat MDR-TB. The
advantages of these molecules include that in vitro to in vivo efﬁcacy
conversion is higher than with purely synthetic compounds; they hit
targets complementary to those identiﬁed in phenotypic screens; they
represent novel chemical classes with different physicochemical
properties from those found in synthetic screening libraries. The
primary disadvantages include that these are often resource intensive
and difﬁcult programs to initiate; the natural product scaffolds are
often of high molecular weight, contain metabolic hotspots, and
have poor consequent oral bioavailability requiring parenteral adminis-
tration; this approach often employs difﬁcult and sometimes costly
chemistry to generate these analogs.
Repurposing existing antibiotics such as β-lactams (faropenem,
meropenem), oxazolidiones (linezolid), and ﬂuoroquinolones
(moxiﬂoxacin) is another productive strategy to identify new MDR-TB
treatment options [5,132]. Linezolid is the prototypical example in
terms of MDR-TB treatment [80]. Its proven efﬁcacy in the treatment
of MDR-TB has generated further studies on sutezolid and AZD5847,
second-generation oxazolidiones with greater mycobacterium selectiv-
ity, and lower side effect potential. This strategy has the advantage of
very rapid advancement into clinical trials, as ample human safety
and PK data often exist. One factor that limits this approach is the num-
ber of new antibacterial agents that are available for repurposing, as the
number of new antibacterial agents approved has dropped signiﬁcantly
in recent years. Currently, the best untapped opportunity for this ap-
proach probably lies in the new wave of β-lactamase inhibitors being
developed to tackle multidrug-resistant Gram-negative bacterial infec-
tions. It remains to be seen if they have sufﬁcient in vivo potency against
Mtb BlaC enzyme [133,134] to enable future β-lactam β-lactamase in-
hibitor combinations tomove forward forMDR-TB. However, the failure
of the recent REMoxTB Phase III clinical trial designed to reduce
treatment time is a cautionary note for this approach [115].
At the time of this writing, 10 Mtb drug clinical trials are registered
in the United States (Table 2), including six compounds classiﬁed as
“novel chemical entities” by the Stop TB Partnership. There are also 3
Phase III trials for optimized combination studies ongoing with
bedaquiline and delamindib and pretomanid (formerly PA-824, another
nitroimidazole) being added to optimized background regimens for pa-
tients with MDR-TB infections. These studies are seeking to enroll more
than 1000 patients suffering fromMDR-TB, including somewho are co-
infected with HIV (NCT00910871, NCT01600963, and NCT01424670).
Fig. 21. Physical chemical properties of currently used therapeutics vs newer agents in the discovery pipeline with their route of administration. The blue-shaded areas indicate the
stereotypical Lipinski's rules for oral bioavailability. cLogP values taken from PubChem database.`
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drugs that are safer and more efﬁcacious with the ability for treatment
shortening is still apparent. A strong discovery pipeline requires many
more agents in early stage trials, as attrition rates increase the further
drugs progress down the pipeline. Thus we believe more new entities
are urgently required, as some of these agents will inevitably fail. It is
our opinion that agents that have good pharmacokinetic propertiesTable 2
List of ongoing and completed clinical trials for newdrugs to treat TB andMDR-TB. Information c
2016.
Drugs Trial no. Phase Sponsor
TBA-354 NCT02288481 1 TB Alliance
Q203 NCT02530710 1 Qurient Co., L
AZD5847 NCT01516203 2 NIAID
Sutezolid NCT00871949 1 Pﬁzer
NCT00990990 1 Pﬁzer
NCT01225640 2 Pﬁzer
SQ109 NCT01218217 2 University of
NCT01585636 1 Sequella, Inc.
NCT01358162 1 NIH
NCT01785186 2 Sequella, Inc.
Clofazimine/Moxiﬂoxacin, Bedaquiline,
Pretomanid, Pyrazinamide
NCT01691534 2 TB Alliance
NCT02193776 2 TB Alliance
Levoﬂoxacin NCT01918397 2 Boston Unive
Bedaquiline with OBR NCT00449644 2 Tibotec BVBA
NCT00910871 2 Tibotec BVBA
NCT01803373 1 Janssen
NCT01464762 3 Janssen
Delaminid with OBR NCT00685360 2 Otsuka Pharm
NCT01424670 3 Otsuka Pharm
NCT01856634 1 Otsuka Pharm
Pretomanid, Moxiﬂoxacin, Pyrazinamide NCT01498419 2 TB Alliance
NCT01215851 2 TB Alliance
NCT02342886 3 TB Allianceincluding caseum penetration and antitubercular activity in this
environment are most needed.
In conclusion, as outlined in this review, it is evident that the discov-
ery and development of new agents to treat Mtb is a very active drug
discovery ﬁeld with many agents in preclinical development. This area
is, however, not without major challenges. Today, we are nowhere
close to achieving the often-stated primary goal of developing a shorter,ompiled from StopTB Partnership (www.newtbdrugs.org) and ClinicalTrials.gov as of April
Start
date
Target patient
enrollment
Status
Jan-15 48 Closed
td. Aug-15 56 Open (Recruiting)
Dec-12 75 Closed
May-09 19 Closed
Nov-09 59 Closed
Aug-11 59 Closed
Munich/Sequella Dec-10 90 Closed
Nov-10 62 Closed
Nov-10 10 Closed
, PanACEA, EDCTP April-13 365 Closed
Oct-12 105 Unknown
Nov-15 240 Open (Not recruiting)
rsity Jan-15 100 Open (Recruiting)
May-07 208 Closed
Jul-09 225 Closed
Mar-13 36 Closed
Oct-11 N/A Open
aceutical Apr-08 481 Closed
aceutical Sep-11 390 Closed
aceutical May-13 12 Open (Recruiting Pediatrics)
Mar-12 230 Closed
Oct-10 85 Closed
Jan-15 1500 On hold
69D.T. Hoagland et al. / Advanced Drug Delivery Reviews 102 (2016) 55–72more effective therapeutic regimen for drug-susceptible TB. There are
worryingly few drugs currently in early stage clinical trials with only 2
compounds in phase I. There are alsomajor pharmacological redundan-
cies with many of the new agents in the pipeline that share a similar
mechanism of action, cross-resistance and/or side effect proﬁles and
thus cannot be used in combination together. The discovery and devel-
opment of new antibiotics in general is difﬁcult due to inherent safety
concerns relating to high and frequent compound dosing of agents
required in comparison to other classes of human medicines. These
problems are further compounded in the therapy of tuberculosis by
the long treatment times and mandatory combination therapy such
that toxicities may not become apparent until late-stage clinical trials
with large patient enrollments. The ﬁeld also faces ﬁnancial and logisti-
cal challenges compounded by the long development times for
compounds and slow rate of discovery requiring a very long-term com-
mitment, whichmany sponsoring agencies and pharmaceutical compa-
nies struggle to maintain, as these timelines aremuch slower than their
usual business cycles. Examples of this problem include the entrance
and exit of pharmaceutical companies such as Novartis, Vertex, and
AstraZeneca, and the recent reduction in support for TB drug discovery
efforts in the European Union. Fortunately, some agencies such as the
NIAID, WHO, and Bill and Melinda Gates Foundation are committed to
the long term, playing critical roles in both raising awareness and secur-
ing desperately needed funding to continue fueling growth and devel-
opment in this ﬁeld. To tackle some of the drug discovery issues, large
consortia of investigators comprising academics and industrial mem-
bers have been formed, such as the TB drug accelerator, NewMedicines
for Tuberculosis (NM4TB) in addition to thework of the TB alliance and
the Critical Path Institute. These consortia offer venues to share comple-
mentary expertise and tackle complex problems. These units havemade
notable progress as evidenced by discovery and development of the
benzothiazone class developed by NM4TB. However, there is a propen-
sity for large conglomerate organizations to become slowedby the com-
peting priorities within the groupings, such that the overall return on
the sum of investment in terms of delivery of new preclinical and
clinical candidates has been less than had been hoped for at the time
of their formation.
In conclusion, despite the challenges outlined we ﬁrmly believe the
ﬁeld of tuberculosis drug discovery ismuch better placed to achieve sig-
niﬁcant therapeutic advances in the coming decade. This results from a
much-improved understanding of Mtb life cycle, the pharmacological
requirements for successful Mtb drugs, and the new antitubercular
chemical matter derived in recent years. The importance of recent im-
provements in animal infectionmodels that bettermimic the pathology
of the human tuberculosis lung, coupled with new imaging technolo-
gies, provide us with much better predictive preclinical models to pro-
duce drug combinations efﬁcacious against hard to treat slow growing
sub-populations, should not be understated. Finally, we believe there
is much strength in the expertise, experience and diversity of investiga-
tors currently working in this area, which needs to be nurtured to
continue the important ﬁght against MDR-TB.Acknowledgments
This study was supported by U.S. National Institutes of Health
(NIH) grants AI090810 and the American Lebanese Syrian Associated
Charities, St. Jude Children's Research Hospital. We thank Dr. Angela
McArthur for assistance in editing this article and Timothy Hammond
for assistance in preparation of the color ﬁgures.References
[1] I. Comas, M. Coscolla, T. Luo, S. Borrell, K.E. Holt, M. Kato-Maeda, J. Parkhill, B. Malla,
S. Berg, G. Thwaites, D. Yeboah-Manu, G. Bothamley, J. Mei, L. Wei, S. Bentley, S.R.
Harris, S. Niemann, R. Diel, A. Aseffa, Q. Gao, D. Young, S. Gagneux, Out-of-Africamigration and Neolithic coexpansion of Mycobacterium tuberculosis with modern
humans, Nat. Genet. 45 (2013) 1176–1182.
[2] WHO, WHO Global Tuberculosis Report 2014, 2014.
[3] F. Luciani, S.A. Sisson, H. Jiang, A.R. Francis, M.M. Tanaka, The epidemiological ﬁt-
ness cost of drug resistance in Mycobacterium tuberculosis, Proc. Natl. Acad. Sci.
106 (2009) 14711–14715.
[4] Z.F. Udwadia, R.A. Amale, K.K. Ajbani, C. Rodrigues, Totally drug-resistant tubercu-
losis in India, Clin. Infect. Dis. 54 (2012) 579–581.
[5] A. Zumla, P. Nahid, S.T. Cole, Advances in the development of new tuberculosis
drugs and treatment regimens, Nat. Rev. Drug Discov. 12 (2013) 388–404.
[6] F. Drobniewski, Is death inevitablewithmultiresistant TB plus HIV infection, Lancet
349 (1997) 71–73.
[7] R.A.M. Breen, Tuberculosis and HIV co-infection: a practical therapeutic approach,
Drugs 66 (2006) 2299–2308.
[8] D.M. Burger, Pharmacokinetic interaction between rifampin and zidovudine,
Antimicrob. Agents Chemother. 37 (1993) 1426–1432.
[9] M. Niemi, Pharmacokinetic interactions with rifampicin: clinical relevance, Clin.
Pharmacokinet. 42 (2003) 819–851.
[10] S. Esposito, L. D'Ambrosio, M. Tadolini, H.S. Schaaf, J. Caminero Luna, B. Marais, R.
Centis, M. Dara, A. Matteelli, F. Blasi, G.B. Migliori, ERS/WHO tuberculosis consilium
assistance with extensively drug-resistant tuberculosis management in a child:
case study of compassionate delamanid use, Eur. Respir. J. 44 (2014) 811–815.
[11] K. Marisa, W. Robin Mark, H. Cindy, P. Nicolaas Claudius Gey van, S. Elizabeth
Maria, M. Borna, S. Frederick Adriaan, C.-N. Mamisa, H. Ebrahim, C. Gerrit, H.
Paul David van, V. Thomas Calldo, T. André Phillip, Emergence and spread of exten-
sively and totally drug-resistant tuberculosis, South Africa, Emerg. Infect. Dis. J. 19
(2013) 449.
[12] M. Raviglione, XDR-TB: entering the post-antibiotic era? Int. J. Tuberc. Lung Dis. 10
(2006) 1185–1187.
[13] K. Kumar, I. Abubakar, Clinical implications of the global multidrug-resistant tuber-
culosis epidemic, Clin. Med. 15 (2015) s37–s42.
[14] M.T. Gler, V. Skripconoka, E. Sanchez-Garavito, H. Xiao, J.L. Cabrera-Rivero, D.E.
Vargas-Vasquez, M. Gao, M. Awad, S.K. Park, T.S. Shim, G.Y. Suh, M. Danilovits, H.
Ogata, A. Kurve, J. Chang, K. Suzuki, T. Tupasi, W.J. Koh, B. Seaworth, L.J. Geiter,
C.D. Wells, Delamanid for multidrug-resistant pulmonary tuberculosis, N. Engl. J.
Med. 366 (2012) 2151–2160.
[15] J. Cohen, Approval of novel TB drug celebrated—with restraint, Science 339 (2013)
130.
[16] N. Ryan, J. Lo, Delamanid: ﬁrst global approval, Drugs 74 (2014) 1041–1045.
[17] K.A. Cohen, W.R. Bishai, A.S. Pym, Molecular basis of drug resistance inMycobacte-
rium tuberculosis, Microbiol. Spectr. 2 (2014).
[18] J. Palomino, A. Martin, Drug resistance mechanisms inMycobacterium tuberculosis,
Antibiotics 3 (2014) 317.
[19] J.D. Fonseca, G.M. Knight, T.D. McHugh, The complex evolution of antibiotic resis-
tance in Mycobacterium tuberculosis, Int. J. Infect. Dis. 32 (2015) 94–100.
[20] S. Gagneux, C.D. Long, P.M. Small, T. Van, G.K. Schoolnik, B.J. Bohannan, The com-
petitive cost of antibiotic resistance in Mycobacterium tuberculosis, Science 312
(2006) 1944–1946.
[21] N. Casali, V. Nikolayevskyy, Y. Balabanova, S.R. Harris, O. Ignatyeva, I. Kontsevaya, J.
Corander, J. Bryant, J. Parkhill, S. Nejentsev, R.D. Horstmann, T. Brown, F.
Drobniewski, Evolution and transmission of drug-resistant tuberculosis in a
Russian population, Nat. Genet. 46 (2014) 279–286.
[22] V. Dartois, The path of anti-tuberculosis drugs: from blood to lesions to mycobac-
terial cells, Nat. Rev. Microbiol. 12 (2014) 159–167.
[23] A. Koul, N. Dendouga, K. Vergauwen, B. Molenberghs, L. Vranckx, R. Willebrords, Z.
Ristic, H. Lill, I. Dorange, J. Guillemont, D. Bald, K. Andries, Diarylquinolines target
subunit c of mycobacterial ATP synthase, Nat. Chem. Biol. 3 (2007) 323–324.
[24] A.H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C.
Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J.C. Palomino,
T. De Marez, R.P. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K.
de Beule, K. Andries, D.F. Mc Neeley, The diarylquinoline TMC207 for multidrug-
resistant tuberculosis, N. Engl. J. Med. 360 (2009) 2397–2405.
[25] K. Andries, P. Verhasselt, J. Guillemont, H.W.H. Göhlmann, J.-M. Neefs, H. Winkler, J.
Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S.
Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, V. Jarlier, A diarylquinoline drug
active on the ATP synthase of Mycobacterium tuberculosis, Science 307 (2005)
223–227.
[26] S. Watanabe, M. Zimmermann, M.B. Goodwin, U. Sauer, C.E. Barry III, H.I. Boshoff,
Fumarate reductase activity maintains an energized membrane in anaerobic
Mycobacterium tuberculosis, PLoS Pathog. 7 (2011), e1002287.
[27] N. Lounis, T. Gevers, J. Van Den Berg, K. Andries, Impact of the interaction of
R207910 with rifampin on the treatment of tuberculosis studied in the mouse
model, Antimicrob. Agents Chemother. 52 (2008) 3568–3572.
[28] L. Preiss, J.D. Langer, Ö. Yildiz, L. Eckhardt-Strelau, J.E.G. Guillemont, A. Koul, T.
Meier, Structure of the mycobacterial ATP synthase Fo rotor ring in complex
with the anti-TB drug bedaquiline, Sci. Adv. 1 (2015).
[29] K. Pethe, P. Bifani, J. Jang, S. Kang, S. Park, S. Ahn, J. Jiricek, J. Jung, H.K. Jeon, J.
Cechetto, T. Christophe, H. Lee, M. Kempf, M. Jackson, A.J. Lenaerts, H. Pham, V.
Jones, M.J. Seo, Y.M. Kim, M. Seo, J.J. Seo, D. Park, Y. Ko, I. Choi, R. Kim, S.Y. Kim,
S. Lim, S.A. Yim, J. Nam, H. Kang, H. Kwon, C.T. Oh, Y. Cho, Y. Jang, J. Kim, A.
Chua, B.H. Tan, M.B. Nanjundappa, S.P. Rao, W.S. Barnes, R. Wintjens, J.R. Walker,
S. Alonso, S. Lee, J. Kim, S. Oh, T. Oh, U. Nehrbass, S.J. Han, Z. No, J. Lee, P. Brodin,
S.N. Cho, K. Nam, J. Kim, Discovery of Q203, a potent clinical candidate for the
treatment of tuberculosis, Nat. Med. 19 (2013) 1157–1160.
[30] K.A. Abrahams, J.A.G. Cox, V.L. Spivey, N.J. Loman, M.J. Pallen, C. Constantinidou, R.
Fernández, C. Alemparte, M.J. Remuiñán, D. Barros, L. Ballell, G.S. Besra,
70 D.T. Hoagland et al. / Advanced Drug Delivery Reviews 102 (2016) 55–72Identiﬁcation of novel Imidazo[1,2-a]pyridine inhibitors targetingM. tuberculosis
QcrB, PLoS ONE 7 (2012), e52951.
[31] G.C. Moraski, P.A. Miller, M.A. Bailey, J. Ollinger, T. Parish, H.I. Boshoff, S. Cho, J.R.
Anderson, S. Mulugeta, S.G. Franzblau, M.J. Miller, Putting tuberculosis (TB) to
rest: transformation of the Sleep Aid, Ambien, and “Anagrams” generated potent
antituberculosis agents, ACS Infect. Dis. 1 (2015) 85–90.
[32] R.E. Lee, K. Mikusova, P.J. Brennan, G.S. Besra, Synthesis of the arabinose donor
.beta.-D-arabinofuranosyl-1-monophosphoryldecaprenol, development of a basic
arabinosyl-transferase assay, and identiﬁcation of ethambutol as an arabinosyl
transferase inhibitor, J. Am. Chem. Soc. 117 (1995) 11829–11832.
[33] B.A. Wolucka, Biosynthesis of D-arabinose in mycobacteria—a novel bacterial
pathway with implications for antimycobacterial therapy, FEBS J. 275 (2008)
2691–2711.
[34] R.C. Goldman, Why are membrane targets discovered by phenotypic screens and
genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb.) 93
(2013) 569–588.
[35] G. Riccardi, M. Pasca, L. Chiarelli, G. Manina, A. Mattevi, C. Binda, The DprE1 en-
zyme, one of the most vulnerable targets of Mycobacterium tuberculosis, Appl.
Microbiol. Biotechnol. 97 (2013) 8841–8848.
[36] V. Makarov, G. Manina, K. Mikusova, U. Möllmann, O. Ryabova, B. Saint-Joanis, N.
Dhar, M.R. Pasca, S. Buroni, A.P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A.
Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J.D.
McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I.
Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R.K. Shandil, V.
Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, S.T. Cole,
Benzothiazinones kill Mycobacterium tuberculosis by blocking Arabinan synthesis,
Science 324 (2009) 801–804.
[37] V. Makarov, B. Lechartier, M. Zhang, J. Neres, A.M. van der Sar, S.A. Raadsen, R.C.
Hartkoorn, O.B. Ryabova, A. Vocat, L.A. Decosterd, N. Widmer, T. Buclin, W. Bitter,
K. Andries, F. Pojer, P.J. Dyson, S.T. Cole, Towards a new combination therapy for
tuberculosis with next generation benzothiazinones, EMBO Mol. Med. 6 (2014)
372–383.
[38] C. Trefzer, M. Rengifo-Gonzalez, M.J. Hinner, P. Schneider, V. Makarov, S.T.
Cole, K. Johnsson, Benzothiazinones: prodrugs that covalently modify the
decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 ofMycobacterium tubercu-
losis, J. Am. Chem. Soc. 132 (2010) 13663–13665.
[39] M. Matsumoto, H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki,
Y. Shimokawa, M. Komatsu, OPC-67683, a nitro-dihydro-imidazooxazole deriva-
tive with promising action against tuberculosis in vitro and in mice, PLoS Med. 3
(2006), e466.
[40] P.S. Shirude, R. Shandil, C. Sadler, M. Naik, V. Hosagrahara, S. Hameed, V.
Shinde, C. Bathula, V. Humnabadkar, N. Kumar, J. Reddy, V. Panduga, S.
Sharma, A. Ambady, N. Hegde, J. Whiteaker, R.E. McLaughlin, H. Gardner, P.
Madhavapeddi, V. Ramachandran, P. Kaur, A. Narayan, S. Guptha, D. Awasthy, C.
Narayan, J. Mahadevaswamy, K.G. Vishwas, V. Ahuja, A. Srivastava, K.R. Prabhakar,
S. Bharath, R. Kale, M. Ramaiah, N.R. Choudhury, V.K. Sambandamurthy, S.
Solapure, P.S. Iyer, S. Narayanan, M. Chatterji, Azaindoles: noncovalent DprE1
inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are
efﬁcacious in vivo, J. Med. Chem. 56 (2013) 9701–9708.
[41] P.S. Shirude, R.K. Shandil, M.R. Manjunatha, C. Sadler, M. Panda, V. Panduga, J.
Reddy, R. Saralaya, R. Nanduri, A. Ambady, S. Ravishankar, V.K. Sambandamurthy,
V. Humnabadkar, L.K. Jena, R.S. Suresh, A. Srivastava, K.R. Prabhakar, J. Whiteaker,
R.E. McLaughlin, S. Sharma, C.B. Cooper, K. Mdluli, S. Butler, P.S. Iyer, S.
Narayanan, M. Chatterji, Lead optimization of 1,4-azaindoles as antimycobacterial
agents, J. Med. Chem. 57 (2014) 5728–5737.
[42] P.R. Donald, H.S. Schaaf, Old and new drugs for the treatment of tuberculosis in
children, Paediatr. Respir. Rev. 8 (2007) 134–141.
[43] F. Wang, D. Sambandan, R. Halder, J. Wang, S.M. Batt, B. Weinrick, I. Ahmad, P.
Yang, Y. Zhang, J. Kim, M. Hassani, S. Huszar, C. Trefzer, Z. Ma, T. Kaneko, K.E.
Mdluli, S. Franzblau, A.K. Chatterjee, K. Johnsson, K. Mikusova, G.S. Besra, K.
Fütterer, S.H. Robbins, S.W. Barnes, J.R.Walker, W.R. Jacobs, P.G. Schultz, Identiﬁca-
tion of a small molecule with activity against drug-resistant and persistent
tuberculosis, Proc. Natl. Acad. Sci. 110 (2013) E2510–E2517.
[44] D.G.N. Muttucumaru, G. Roberts, J. Hinds, R.A. Stabler, T. Parish, Gene expression
proﬁle of Mycobacterium tuberculosis in a non-replicating state, Tuberculosis 84
(2004) 239–246.
[45] P. Domenech, M.B. Reed, C.E. Barry, Contribution of theMycobacterium tuberculosis
MmpL protein family to virulence and drug resistance, Infect. Immun. 73 (2005)
3492–3501.
[46] R.E. Lee, M. Protopopova, E. Crooks, R.A. Slayden, M. Terrot, C.E. Barry, Combinato-
rial lead optimization of [1,2]-diamines based on ethambutol as potential antitu-
berculosis preclinical candidates, J. Comb. Chem. 5 (2003) 172–187.
[47] M. Biava, G.C. Porretta, F. Manetti, New derivatives of BM212: A class of
antimycobacterial compounds based on the pyrrole ring as a scaffold, Mini-Rev.
Med. Chem. 7 (2007) 65–78.
[48] W. Li, A. Upadhyay, F.L. Fontes, E.J. North, Y. Wang, D.C. Crans, A.E. Grzegorzewicz,
V. Jones, S.G. Franzblau, R.E. Lee, D.C. Crick, M. Jackson, Novel insights into the
mechanism of inhibition of MmpL3, a target of multiple pharmacophores inMyco-
bacterium tuberculosis, Antimicrob. Agents Chemother. 58 (2014) 6413–6423.
[49] G. Poce, R.H. Bates, S. Alfonso, M. Cocozza, G.C. Porretta, L. Ballell, J. Rullas, F. Ortega,
A. De Logu, E. Agus, V. La Rosa, M.R. Pasca, E. De Rossi, B. Wae, S.G. Franzblau, F.
Manetti, M. Botta, M. Biava, Improved BM212MmpL3 inhibitor analogue shows ef-
ﬁcacy in acute murine model of tuberculosis infection, PLoS One 8 (2013), e56980.
[50] K. Li, L.A. Schurig-Briccio, X. Feng, A. Upadhyay, V. Pujari, B. Lechartier, F.L. Fontes,
H. Yang, G. Rao, W. Zhu, A. Gulati, J.H. No, G. Cintra, S. Bogue, Y.-L. Liu, K. Molohon,
P. Orlean, D.A. Mitchell, L. Freitas-Junior, F. Ren, H. Sun, T. Jiang, Y. Li, R.-T. Guo, S.T.Cole, R.B. Gennis, D.C. Crick, E. Oldﬁeld, Multitarget drug discovery for tuberculosis
and other infectious diseases, J. Med. Chem. 57 (2014) 3126–3139.
[51] S.P. Rao, S.B. Lakshminarayana, R.R. Kondreddi, M. Herve, L.R. Camacho, P. Bifani,
S.K. Kalapala, J. Jiricek, N.L. Ma, B.H. Tan, S.H. Ng, M. Nanjundappa, S. Ravindran,
P.G. Seah, P. Thayalan, S.H. Lim, B.H. Lee, A. Goh, W.S. Barnes, Z. Chen, K.
Gagaring, A.K. Chatterjee, K. Pethe, K. Kuhen, J. Walker, G. Feng, S. Babu, L. Zhang,
F. Blasco, D. Beer, M. Weaver, V. Dartois, R. Glynne, T. Dick, P.W. Smith, T.T.
Diagana, U.H. Manjunatha, Indolcarboxamide is a preclinical candidate for treating
multidrug-resistant tuberculosis, Sci. Transl. Med. 5 (2013) (214ra168).
[52] S. Lun, H. Guo, O.K. Onajole, M. Pieroni, H. Gunosewoyo, G. Chen, S.K. Tipparaju,
N.C. Ammerman, A.P. Kozikowski, W.R. Bishai, Indoleamides are active against
drug-resistant Mycobacterium tuberculosis, Nat. Commun. 4 (2013).
[53] H.T. Wright, K.A. Reynolds, Antibacterial targets in fatty acid biosynthesis, Curr.
Opin. Microbiol. 10 (2007) 447–453.
[54] Y.-M. Zhang, S.W. White, C.O. Rock, Inhibiting bacterial fatty acid synthesis, J. Biol.
Chem. 281 (2006) 17541–17544.
[55] H.-J. Li, C.-T. Lai, P. Pan, W. Yu, N. Liu, G.R. Bommineni, M. Garcia-Diaz, C.
Simmerling, P.J. Tonge, A structural and energetic model for the slow-onset inhibi-
tion of theMycobacterium tuberculosis Enoyl-ACP reductase InhA, ACS Chem. Biol.
9 (2014) 986–993.
[56] R. Rawat, A. Whitty, P.J. Tonge, The isoniazid-NAD adduct is a slow, tight-binding
inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct afﬁnity
and drug resistance, Proc. Natl. Acad. Sci. 100 (2003) 13881–13886.
[57] C.-T. Lai, H.-J. Li, W. Yu, S. Shah, G.R. Bommineni, V. Perrone, M. Garcia-Diaz, P.J.
Tonge, C. Simmerling, Rational modulation of the induced-ﬁt conformational
change for slow-onset inhibition inMycobacterium tuberculosis InhA, Biochemistry
54 (2015) 4683–4691.
[58] H. Lu, P.J. Tonge, Drug–target residence time: critical information for lead optimi-
zation, Curr. Opin. Chem. Biol. 14 (2010) 467–474.
[59] P.J. Tummino, R.A. Copeland, Residence time of receptor—ligand complexes and its
effect on biological function, Biochemistry 47 (2008) 5481–5492.
[60] R.A. Copeland, D.L. Pompliano, T.D. Meek, Drug-target residence time and its impli-
cations for lead optimization, Nat. Rev. Drug Discov. 5 (2006) 730–739.
[61] H. Lu, K. England, C. am Ende, J.J. Truglio, S. Luckner, B.G. Reddy, N.L. Marlenee, S.E.
Knudson, D.L. Knudson, R.A. Bowen, C. Kisker, R.A. Slayden, P.J. Tonge, Slow-onset
inhibition of the fabi enoyl reductase from Francisella tularensis: residence time
and in vivo activity, ACS Chem. Biol. 4 (2009) 221–231.
[62] N. Kaplan, M. Albert, D. Awrey, E. Bardouniotis, J. Berman, T. Clarke, M. Dorsey, B.
Hafkin, J. Ramnauth, V. Romanov, M.B. Schmid, R. Thalakada, J. Yethon, H.W.
Pauls, Mode of action, in vitro activity, and in vivo efﬁcacy of AFN-1252, a selective
antistaphylococcal FabI inhibitor, Antimicrob. Agents Chemother. 56 (2012)
5865–5874.
[63] S. Escaich, L. Prouvensier, M. Saccomani, L. Durant, M. Oxoby, V. Gerusz, F. Moreau,
V. Vongsouthi, K. Maher, I. Morrissey, C. Soulama-Mouze, The MUT056399 inhibi-
tor of FabI is a new antistaphylococcal compound, Antimicrob. Agents Chemother.
55 (2011) 4692–4697.
[64] R. Šink, I. Sosič, M. Živec, R. Fernandez-Menendez, S. Turk, S. Pajk, D. Alvarez-
Gomez, E.M. Lopez-Roman, C. Gonzales-Cortez, J. Rullas-Triconado, I. Angulo-
Barturen, D. Barros, L. Ballell-Pages, R.J. Young, L. Encinas, S. Gobec, Design, synthe-
sis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier
protein reductase (InhA) for the treatment of tuberculosis, J. Med. Chem. 58
(2015) 613–624.
[65] P.S. Shirude, P. Madhavapeddi, M. Naik, K. Murugan, V. Shinde, R. Nandishaiah, J.
Bhat, A. Kumar, S. Hameed, G. Holdgate, G. Davies, H. McMiken, N. Hegde, A.
Ambady, J. Venkatraman, M. Panda, B. Bandodkar, V.K. Sambandamurthy, J.A.
Read, Methyl-thiazoles: a novel mode of inhibition with the potential to develop
novel inhibitors targeting InhA in Mycobacterium tuberculosis, J. Med. Chem. 56
(2013) 8533–8542.
[66] U.H. Manjunatha, S.P.S. Rao, R.R. Kondreddi, C.G. Noble, L.R. Camacho, B.H. Tan, S.H.
Ng, P.S. Ng, N.L. Ma, S.B. Lakshminarayana, M. Herve, S.W. Barnes, W. Yu, K. Kuhen,
F. Blasco, D. Beer, J.R. Walker, P.J. Tonge, R. Glynne, P.W. Smith, T.T. Diagana, Direct
inhibitors of InhA are active againstMycobacterium tuberculosis, Sci. Transl. Med. 7
(2015) (269ra263).
[67] A.B. Keener, Oldie but goodie: repurposing penicillin for tuberculosis, Nat. Med. 20
(2014) 976–978.
[68] J.P. Nadler, J. Berger, J.A. Nord, R. Cofsky, M. Saxena, AMoxicillin-clavulanic acid for
treating drug-resistant Mycobacterium tuberculosis, Chest 99 (1991) 1025–1026.
[69] K.E. Dooley, E.A. Obuku, N. Durakovic, V. Belitsky, C. Mitnick, E.L. Nuermberger,
World Health Organization group 5 drugs for the treatment of drug-resistant tu-
berculosis: unclear efﬁcacy or untapped potential? J. Infect. Dis. 207 (2013)
1352–1358.
[70] V. Dubée, S. Triboulet, J.-L. Mainardi, M. Ethève-Quelquejeu, L. Gutmann, A. Marie,
L. Dubost, J.-E. Hugonnet, M. Arthur, Inactivation ofMycobacterium tuberculosis l,d-
Transpeptidase LdtMt1 by carbapenems and cephalosporins, Antimicrob. Agents
Chemother. 56 (2012) 4189–4195.
[71] C.N. Wivagg, R.P. Bhattacharyya, D.T. Hung, Mechanisms of [beta]-lactam killing
and resistance in the context of Mycobacterium tuberculosis, J. Antibiot. 67 (2014)
645–654.
[72] S. De Lorenzo, J.W. Alffenaar, G. Sotgiu, R. Centis, L. D'Ambrosio, S. Tiberi, M.S.
Bolhuis, R. van Altena, P. Viggiani, A. Piana, A. Spanevello, G.B. Migliori, Efﬁca-
cy and safety of meropenem–clavulanate added to linezolid-containing
regimens in the treatment of MDR−/XDR-TB, Eur. Respir. J. 41 (2013)
1386–1392.
[73] H.F. Chambers, J. Turner, G.F. Schecter, M. Kawamura, P.C. Hopewell, Imipenem for
treatment of tuberculosis in mice and humans, Antimicrob. Agents Chemother. 49
(2005) 2816–2821.
71D.T. Hoagland et al. / Advanced Drug Delivery Reviews 102 (2016) 55–72[74] J.-E. Hugonnet, L.W. Tremblay, H.I. Boshoff, C.E. Barry, J.S. Blanchard, Meropenem–
clavulanate is effective against extensively drug-resistant Mycobacterium tubercu-
losis, Science 323 (2009) 1215–1218.
[75] M.C. Payen, S. DeWit, C. Martin, R. Sergysels, I. Muylle, Y. Van Laethem, N. Clumeck,
Clinical use of the meropenem-clavulanate combination for extensively drug-
resistant tuberculosis, Int. J. Tuberc. Lung Dis. 16 (2012) 558–560.
[76] D. Hoagland, Y. Zhao, R. Lee, Advances in drug discovery and development for
pediatric tuberculosis, Mini-Rev. Med. Chem. 16 (2016) 481–497.
[77] I. Milazzo, G. Blandino, F. Caccamo, R. Musumeci, G. Nicoletti, A. Speciale,
Faropenem, a new oral penem: antibacterial activity against selected anaerobic
and fastidious periodontal isolates, J. Antimicrob. Chemother. 51 (2003) 721–725.
[78] K.N. Schurek, R. Wiebe, J.A. Karlowsky, E. Rubinstein, D.J. Hoban, G.G. Zhanel,
Faropenem: review of a new oral penem, Expert Rev. Anti-Infect. Ther. 5 (2007)
185–198.
[79] N. Dhar, V. Dubée, L. Ballell, G. Cuinet, J.-E. Hugonnet, F. Signorino-Gelo, D. Barros,
M. Arthur, J.D. McKinney, Rapid cytolysis of Mycobacterium tuberculosis by
Faropenem, an orally bioavailable β-lactam antibiotic, Antimicrob. Agents
Chemother. 59 (2015) 1308–1319.
[80] M. Lee, J. Lee, M.W. Carroll, H. Choi, S. Min, T. Song, L.E. Via, L.C. Goldfeder, E. Kang,
B. Jin, H. Park, H. Kwak, H. Kim, H.S. Jeon, I. Jeong, J.S. Joh, R.Y. Chen, K.N. Olivier, P.A.
Shaw, D. Follmann, S.D. Song, J.K. Lee, D. Lee, C.T. Kim, V. Dartois, S.K. Park, S.N. Cho,
C.E. Barry III, Linezolid for treatment of chronic extensively drug-resistant tubercu-
losis, N. Engl. J. Med. 367 (2012) 1508–1518.
[81] D.R. Ashtekar, R. Costa-Periera, T. Shrinivasan, R. Iyyer, N. Vishvanathan, W. Rittel,
Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo
activities of DuP-721 against Mycobacterium tuberculosis, Diagn. Microbiol. Infect.
Dis. 14 (1991) 465–471.
[82] P.C. Rose, U.M. Hallbauer, J.A. Seddon, A.C. Hesseling, H.S. Schaaf, Linezolid-
containing regimens for the treatment of drug-resistant tuberculosis in South
African children, Int. J. Tuberc. Lung Dis. 16 (2012) 1588–1593.
[83] H.A. Anger, F. Dworkin, S. Sharma, S.S. Munsiff, D.M. Nilsen, S.D. Ahuja, Linezolid
use for treatment of multidrug-resistant and extensively drug-resistant tuberculo-
sis, New York City, 2000-06, J. Antimicrob. Chemother. 65 (2010) 775–783.
[84] A.J. Garcia-Prats, P.C. Rose, A.C. Hesseling, H.S. Schaaf, Linezolid for the treatment of
drug-resistant tuberculosis in children: a review and recommendations, Tubercu-
losis (Edinb.) 94 (2014) 93–104.
[85] V. Balasubramanian, S. Solapure, H. Iyer, A. Ghosh, S. Sharma, P. Kaur, R. Deepthi, V.
Subbulakshmi, V. Ramya, V. Ramachandran, M. Balganesh, L. Wright, D. Melnick,
S.L. Butler, V.K. Sambandamurthy, Bactericidal activity and mechanism of action
of AZD5847, a novel oxazolidinone for treatment of tuberculosis, Antimicrob.
Agents Chemother. 58 (2014) 495–502.
[86] D.F. Bruhn, M.S. Scherman, J. Liu, D. Scherbakov, B. Meibohm, E.C. Böttger, A.J.
Lenaerts, R.E. Lee, In vitro and in vivo evaluation of synergism between anti-
tubercular spectinamides and non-classical tuberculosis antibiotics, Sci. Rep. 5
(2015) 13985.
[87] F.L. Rock, W. Mao, A. Yaremchuk, M. Tukalo, T. Crépin, H. Zhou, Y.-K. Zhang, V.
Hernandez, T. Akama, S.J. Baker, J.J. Plattner, L. Shapiro, S.A. Martinis, S.J.
Benkovic, S. Cusack, M.R.K. Alley, An antifungal agent inhibits an aminoacyl-
tRNA synthetase by trapping tRNA in the editing site, Science 316 (2007)
1759–1761.
[88] Q.-H. Hu, R.-J. Liu, Z.-P. Fang, J. Zhang, Y.-Y. Ding, M. Tan, M. Wang, W. Pan, H.-C.
Zhou, E.-D. Wang, Discovery of a potent benzoxaborole-based anti-pneumococcal
agent targeting leucyl-tRNA synthetase, Sci. Rep. 3 (2013).
[89] V. Hernandez, T. Crépin, A. Palencia, S. Cusack, T. Akama, S.J. Baker, W. Bu, L. Feng,
Y.R. Freund, L. Liu, M.Meewan, M.Mohan,W. Mao, F.L. Rock, H. Sexton, A. Sheoran,
Y. Zhang, Y.-K. Zhang, Y. Zhou, J.A. Nieman, M.R. Anugula, E.M. Keramane, K.
Savariraj, D.S. Reddy, R. Sharma, R. Subedi, R. Singh, A. O'Leary, N.L. Simon, P.L.
De Marsh, S. Mushtaq, M. Warner, D.M. Livermore, M.R.K. Alley, J.J. Plattner,
Discovery of a novel class of boron-based antibacterials with activity against
Gram-negative bacteria, Antimicrob. Agents Chemother. 57 (2013) 1394–1403.
[90] J. Davies, Where have all the antibiotics gone? Can. J. Infect. Dis. Med. Microbiol. 17
(2006) 287–290.
[91] M.A. Borovinskaya, S. Shoji, J.M. Holton, K. Fredrick, J.H.D. Cate, A steric block in
translation caused by the antibiotic spectinomycin, ACS Chem. Biol. 2 (2007)
545–552.
[92] C. Kehrenberg, S. Schwarz, Mutations in 16S rRNA and ribosomal protein
S5 associated with high-level spectinomycin resistance in Pasteurella multocida,
Antimicrob. Agents Chemother. 51 (2007) 2244–2246.
[93] R.E. Lee, J.G. Hurdle, J. Liu, D.F. Bruhn, T. Matt, M.S. Scherman, P.K. Vaddady, Z.
Zheng, J. Qi, R. Akbergenov, S. Das, D.B. Madhura, C. Rathi, A. Trivedi, C. Villellas,
R.B. Lee, Rakesh, S.L. Waidyarachchi, D. Sun, M.R. McNeil, J.A. Ainsa, H.I. Boshoff,
M. Gonzalez-Juarrero, B. Meibohm, E.C. Bottger, A.J. Lenaerts, Spectinamides: a
new class of semisynthetic antituberculosis agents that overcome native drug
efﬂux, Nat. Med. 20 (2014) 152–158.
[94] H. Noufﬂard-Guy-Loe, S. Berteaux, Experimental antituberculous action of a new
antibiotic: RP 11,072, Rev. Tuberc. Pneumol. 29 (1965) 301–326.
[95] B. Terlain, J.P. Thomas, Structure of griselimycin, polypeptide antibiotic extracted
from streptomyces cultures. II. Structure of griselimycin, Bull. Soc. Chim. Fr. 6
(1971) 2357–2362.
[96] A. Kling, P. Lukat, D.V. Almeida, A. Bauer, E. Fontaine, S. Sordello, N. Zaburannyi, J.
Herrmann, S.C. Wenzel, C. König, N.C. Ammerman, M.B. Barrio, K. Borchers, F.
Bordon-Pallier, M. Brönstrup, G. Courtemanche, M. Gerlitz, M. Geslin, P.
Hammann, D.W. Heinz, H. Hoffmann, S. Klieber, M. Kohlmann, M. Kurz, C. Lair, H.
Matter, E. Nuermberger, S. Tyagi, L. Fraisse, J.H. Grosset, S. Lagrange, R. Müller,
Targeting DnaN for tuberculosis therapy using novel griselimycins, Science 348
(2015) 1106–1112.[97] V.M. Reddy, L. Einck, C.A. Nacy, In vitro antimycobacterial activities of Capuramycin
Analogues, Antimicrob. Agents Chemother. 52 (2008) 719–721.
[98] B.V. Nikonenko, V.M. Reddy, M. Protopopova, E. Bogatcheva, L. Einck, C.A. Nacy, Ac-
tivity of SQ641, a capuramycin analog, in a murine model of tuberculosis,
Antimicrob. Agents Chemother. 53 (2009) 3138–3139.
[99] B. Nikonenko, V.M. Reddy, E. Bogatcheva, M. Protopopova, L. Einck, C.A. Nacy, Ther-
apeutic efﬁcacy of SQ641-NE against Mycobacterium tuberculosis, Antimicrob.
Agents Chemother. 58 (2014) 587–589.
[100] J.J. Salomon, P. Galeron, N. Schulte, P.R. Morow, D. Severynse-Stevens, H. Huwer, N.
Daum, C.-M. Lehr, A.J. Hickey, C. Ehrhardt, Biopharmaceutical in vitro characteriza-
tion of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis, Ther.
Deliv. 4 (2013) 915–923.
[101] R.C. Hartkoorn, C. Sala, J. Neres, F. Pojer, S. Magnet, R. Mukherjee, S. Uplekar, S. Boy-
Röttger, K.-H. Altmann, S.T. Cole, Towards a new tuberculosis drug: pyridomycin –
nature's isoniazid, EMBO Mol. Med. 4 (2012) 1032–1042.
[102] R.C. Hartkoorn, F. Pojer, J.A. Read, H. Gingell, J. Neres, O.P. Horlacher, K.-H. Altmann,
S.T. Cole, Pyridomycin bridges the NADH- and substrate-binding pockets of the
enoyl reductase InhA, Nat. Chem. Biol. 10 (2014) 96–98.
[103] A.I. Zumla, S.H. Gillespie, M. Hoelscher, P.P.J. Philips, S.T. Cole, I. Abubakar, T.D.
McHugh, M. Schito, M. Maeurer, A.J. Nunn, New antituberculosis drugs, regimens,
and adjunct therapies: needs, advances, and future prospects, Lancet Infect. Dis. 14
(2014) 327–340.
[104] G. Riccardi, M.R. Pasca, Trends in discovery of new drugs for tuberculosis therapy, J.
Antibiot. 67 (2014) 655–659.
[105] K. Mdluli, T. Kaneko, A. Upton, The tuberculosis drug discovery and development
pipeline and emerging drug targets, Cold Spring Harb. Perspect. Med. 5 (2015),
a021154.
[106] T.R. Ioerger, T. O'Malley, R. Liao, K.M. Guinn, M.J. Hickey, N. Mohaideen, K.C.
Murphy, H.I.M. Boshoff, V. Mizrahi, E.J. Rubin, C.M. Sassetti, C.E. Barry III, D.R.
Sherman, T. Parish, J.C. Sacchettini, Identiﬁcation of new drug targets and resis-
tance mechanisms inMycobacterium tuberculosis, PLoS ONE 8 (2013), e75245.
[107] O.T. Schubert, J. Mouritsen, C. Ludwig, H.L. Röst, G. Rosenberger, P.K. Arthur, M.
Claassen, D.S. Campbell, Z. Sun, T. Farrah, M. Gengenbacher, A. Maiolica, S.H.E.
Kaufmann, R.L. Moritz, R. Aebersold, The Mtb Proteome Library: a resource of as-
says to quantify the complete proteome of Mycobacterium tuberculosis, Cell Host
Microbe 13 (2013) 602–612.
[108] K.A. Cohen, T. Abeel, A.M. McGuire, C.A. Desjardins, V. Munsamy, T.P. Shea, B.J.
Walker, N. Bantubani, D.V. Almeida, L. Alvarado, S. Chapman, N.R. Mvelase, E.Y.
Duffy, M.G. Fitzgerald, P. Govender, S. Gujja, S. Hamilton, C. Howarth, J.D.
Larimer, K. Maharaj, M.D. Pearson, M.E. Priest, Q. Zeng, N. Padayatchi, J. Grosset,
S.K. Young, J. Wortman, K.P. Mlisana, M.R. O′Donnell, B.W. Birren, W.R. Bishai,
A.S. Pym, A.M. Earl, Evolution of extensively drug-resistant tuberculosis over four
decades revealed by whole genome sequencing of Mycobacterium tuberculosis
from KwaZulu-Natal, South Africa, Int. J. Mycobacteriol. 4 (Suppl. 1) (2015) 24–25.
[109] C.S. Kuan, C.L. Chan, S.M. Yew, Y.F. Toh, J.-S. Khoo, J. Chong, K.W. Lee, Y.-C. Tan,W.-Y.
Yee, Y.F. Ngeow, K.P. Ng, Genome analysis of the ﬁrst extensively drug-resistant
(XDR) Mycobacterium tuberculosis in Malaysia provides insights into the genetic
basis of its biology and drug resistance, PLoS One 10 (2015), e0131694.
[110] D. Schnappinger, K. O'Brien, S. Ehrt, Construction of conditional knockdown mu-
tants in mycobacteria, in: T. Parish, D.M. Roberts (Eds.), Mycobacteria Protocols,
Springer, New York 2015, pp. 151–175.
[111] S. Woong Park, M. Klotzsche, D.J. Wilson, H.I. Boshoff, H. Eoh, U. Manjunatha, A.
Blumenthal, K. Rhee, C.E. Barry III, C.C. Aldrich, S. Ehrt, D. Schnappinger, Evaluating
the sensitivity ofMycobacterium tuberculosis to biotin deprivation using regulated
gene expression, PLoS Pathog. 7 (2011), e1002264.
[112] B. Gold, T. Warrier, C. Nathan, A multi-stress model for high throughput screening
against non-replicating Mycobacterium tuberculosis, in: T. Parish, D.M. Roberts
(Eds.), Mycobacteria Protocols, Springer, New York 2015, pp. 293–315.
[113] B.C. VanderVen, R.J. Fahey, W. Lee, Y. Liu, R.B. Abramovitch, C. Memmott, A.M.
Crowe, L.D. Eltis, E. Perola, D.D. Deininger, T. Wang, C.P. Locher, D.G. Russell,
Novel inhibitors of cholesterol degradation inMycobacterium tuberculosis reveal
how the bacterium's metabolism is constrained by the intracellular environment,
PLoS Pathog. 11 (2015), e1004679.
[114] B. Prideaux, L.E. Via, M.D. Zimmerman, S. Eum, J. Sarathy, P. O'Brien, C. Chen, F.
Kaya, D.M. Weiner, P.Y. Chen, T. Song, M. Lee, T.S. Shim, J.S. Cho, W. Kim, S.N.
Cho, K.N. Olivier, C.E. Barry III, V. Dartois, The association between sterilizing activ-
ity and drug distribution into tuberculosis lesions, Nat. Med. 21 (2015) 1223–1227.
[115] S.H. Gillespie, A.M. Crook, T.D. McHugh, C.M. Mendel, S.K. Meredith, S.R. Murray, F.
Pappas, P.P.J. Phillips, A.J. Nunn, Four-month moxiﬂoxacin-based regimens for
drug-sensitive tuberculosis, N. Engl. J. Med. 371 (2014) 1577–1587.
[116] M.C. Kjellsson, L.E. Via, A. Goh, D. Weiner, K.M. Low, S. Kern, G. Pillai, C.E. Barry,
V. Dartois, Pharmacokinetic evaluation of the penetration of antituberculosis
agents in rabbit pulmonary lesions, Antimicrob. Agents Chemother. 56
(2012) 446–457.
[117] J.-M. Michot, C. Seral, F. Van Bambeke, M.-P. Mingeot-Leclercq, P.M. Tulkens,
Inﬂuence of efﬂux transporters on the accumulation and efﬂux of four quinolones
(ciproﬂoxacin, levoﬂoxacin, garenoxacin, and moxiﬂoxacin) in J774 macrophages,
Antimicrob. Agents Chemother. 49 (2005) 2429–2437.
[118] W.R. Barclay, R.H. Ebert, G.V. Le Roy, R.W. Manthei, L.J. Roth, Distribution and
excretion of radioactive isoniazid in tuberculous patients, J. Am. Med. Assoc. 151
(1953) 1384–1388.
[119] G. Canetti, R. Parrot, G. Porven, M. Le Lirzin, Rifomycin levels in the lung and tuber-
culous lesions in man, Acta Tuberc. Pneumol. Belg. 60 (1969) 315–322.
[120] G.A. Ellard, M.J. Humphries, B.W. Allen, Cerebrospinal ﬂuid drug concentrations
and the treatment of tuberculous meningitis, Am. Rev. Respir. Dis. 148 (1993)
650–655.
72 D.T. Hoagland et al. / Advanced Drug Delivery Reviews 102 (2016) 55–72[121] G.A. Ellard, M.J. Humphries, M. Gabriel, R. Teoh, Penetration of pyrazinamide into
the cerebrospinal ﬂuid in tuberculous meningitis, Br. Med. J. (Clin. Res. Ed.) 294
(1987) 284–285.
[122] B. Prideaux, V. Dartois, D. Staab, D.M. Weiner, A. Goh, L.E. Via, C.E. Barry III, M.
Stoeckli, High-sensitivity MALDI-MRM-MS imaging of moxiﬂoxacin distribution
in tuberculosis-infected rabbit lungs and granulomatous lesions, Anal. Chem. 83
(2011) 2112–2118.
[123] B. Prideaux, M. Stoeckli, Mass spectrometry imaging for drug distribution studies, J.
Proteome 75 (2012) 4999–5013.
[124] S.T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S.V. Gordon, K.
Eiglmeier, S. Gas, C.E. Barry, F. Tekaia, K. Badcock, D. Basham, D. Brown, T.
Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S.
Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver,
J. Osborne, M.A. Quail, M.A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton,
R. Squares, S. Squares, J.E. Sulston, K. Taylor, S.Whitehead, B.G. Barrell, Deciphering
the biology of Mycobacterium tuberculosis from the complete genome sequence,
Nature 393 (1998) 537–544.
[125] E.D. Brown, G.D. Wright, New targets and screening approaches in antimicrobial
drug discovery, Chem. Rev. 105 (2005) 759–774.
[126] T. Wunberg, M. Hendrix, A. Hillisch, M. Lobell, H. Meier, C. Schmeck, H. Wild, B.
Hinzen, Improving the hit-to-lead process: data-driven assessment of drug-like
and lead-like screening hits, Drug Discov. Today 11 (2006) 175–180.
[127] M. Elinder, M. Geitmann, T. Gossas, P. Källblad, J. Winquist, H. Nordström, M.
Hämäläinen, U.H. Danielson, Experimental validation of a fragment libraryfor lead discovery using SPR biosensor technology, J. Biomol. Screen. 16
(2011) 15–25.
[128] J.R. Brown, E.J. North, J.G. Hurdle, C. Morisseau, J.S. Scarborough, D. Sun, J.
Kordulakova, M.S. Scherman, V. Jones, A. Grzegorzewicz, R.M. Crew, M. Jackson,
M.R. McNeil, R.E. Lee, The structure–activity relationship of urea derivatives as
anti-tuberculosis agents, Bioorg. Med. Chem. 19 (2011) 5585–5595.
[129] G.M. Keseru, G.M. Makara, The inﬂuence of lead discovery strategies on the
properties of drug candidates, Nat. Rev. Drug Discov. 8 (2009) 203–212.
[130] C. Lipinski, Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 23
(1997) 3–25.
[131] C. Lipinski, Drug-like properties and the causes of poor solubility and poor
permeability, J. Pharmacol. Toxicol. Methods 44 (2000) 235–249.
[132] A.Maitra, S. Bates, T. Kolvekar, P.V. Devarajan, J.D. Guzman, S. Bhakta, Repurposing—a
ray of hope in tackling extensively drug resistance in tuberculosis, Int. J. Infect. Dis. 32
(2015) 50–55.
[133] D. Zhang, Y. Wang, J. Lu, Y. Pang, In vitro activity of β-lactams in combination with
β-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis
isolates, Antimicrob. Agents Chemother. 60 (2015) 393–399.
[134] S. Hazra, H. Xu, J.S. Blanchard, Tebipenem, a new carbapenem antibiotic, Is a Slow
Substrate That Inhibits the β-Lactamase from Mycobacterium tuberculosis,
Biochemistry 53 (2014) 3671–3678.
